

## miR-24 and its target gene Prdx6 regulate viability and senescence of myogenic progenitors during aging

| Journal:                      | Aging Cell   |
|-------------------------------|--|
| Manuscript ID                 | ACE-21-0072.R1   |
| Wiley - Manuscript type:      | Original Paper   |
| Date Submitted by the Author: | n/a  |
| Complete List of Authors:     | Soriano Arroquia, Ana; Institute of Ageing and Chronic Disease, Musculoskeletal Biology Gostage, John; The University of Sheffield Xia, Qin; National University of Ireland Galway, Physiology Bardell, David; Institute of Ageing and Chronic Disease, Musculoskeletal Biology McCormick, Rachel; Institute of Ageing and Chronic Disease, Musculoskeletal Biology McCloskey, Eugene; The University of Sheffield Bellantuono, Ilaria; The University of Sheffield Clegg, Peter; Institute of Ageing and Chronic Disease, Musculoskeletal Biology McDonagh, Brian; National University of Ireland Galway College of Medicine Nursing and Health Sciences, Physiology Whysall, Katarzyna; Institute of Ageing and Chronic Disease, Musculoskeletal Biology |
| Keywords:                     | Aging, skeletal muscle, microRNA, oxidative stress, miR-24, cellular senescence  |
|                               |  |

SCHOLARONE™ Manuscripts Founded in 1845

Dr Katarzyna Goljanek-Whysall Discipline of Physiology School of Medicine NUI Galway, Ireland

Tel: +353 91494299 kasia.whysall@nuigalway.ie

13th July 2021

Dear Prof Antebi,

Thank you for the initial assessment of our manuscript (ACE-21-0072) and the reviewer comments sent on the 6<sup>th</sup> of April. Clarification of the role of Prdx6 in satellite cells ageing in addition to its characterisation as miR-24 target gene was requested. We have now repeated all the experiments performed in the first version of this manuscript using miR-24 mimic and inhibitor with the addition of another condition: cell transfected with Prdx6 siRNA. Several key reagents, such as miR-24 inhibitor or Prdx6 siRNA have been discontinued (indicated in supplementary data) since we collected original data, therefore we decided to repeat all experiments. We have included additional analyses of mitochondrial ROS, mitochondrial morphology, DNA damage and additional assays of senescence.

The results obtained confirm our previous findings that both treatment with miR-24 mimic and downregulation of Prdx6 using siRNA resulted in reduced viability, decreased myogenic potential and increased senescence during aging. In summary, our results identify a role for miR-24-3p through inhibition of Prdx6 in satellite cells during aging which may play a key role in early stages of skeletal muscle regeneration after acute injury, through controlling adaptive redox, apoptotic and senescence signalling pathways. Moreover, our findings show that miR-24 and Prdx6 regulation of myogenic progenitor phenotype is more pronounced in cells from old mice, likely due to miR-24 regulation of additional to Prdx6 target genes, such as p21.

Considering the number of additional experiments that were performed we propose joint first name authorship to the first two authors (Soriano-Arroquia and Gostage). We also had significant input for a number of experiments from PhD candidate Qin Xia and believe their contribution warrants authorship on the manuscript. We believe the additional experiments and overall editing have significantly improved the manuscript and it could now be reconsidered for publication in *Aging Cell*.

We hope you will find the revised article appropriate for publication in *Aging Cell* and look forward to your reply.

Yours sincerely,

kuyal

Dr Katarzyna Goljanek-Whysall Senior Lecturer in Physiology School of Medicine NUI Galway

NUI Galway Ireland

Email: kasia.whysall@nuigalway.ie

Aging Cell Page 2 of 50

### ACE-21-0072 miR-24:Prdx6 interactions regulate oxidative stress and viability of myogenic progenitors during aging

#### Response to reviewer comments

#### **Editor comments:**

As you can read below, the reviewers and supervising editor were interested in the possible functional interaction of mir-24/prd6, but felt that that several points about this interaction with respect to aging needed clarification, as well as the relationship to ROS. Furthermore, the statistical analysis needs to be addressed.

The review of your manuscript is complete, and the reviewers found the manuscript of interest, relevant for Aging Cell and will appeal to a wide readership. The reviewers ask for revisions of the manuscript requiring more details regarding the use of t-tests for statistical significance, resolution of apparent inconsistencies among experiments, particularly with regard to the effects of miR24 antagomiRs and miR24 in aged and young mice.

We would like to thank the reviewers and the editors insightful comments and an opportunity to improve this manuscript. We have addressed all the comments – please see below.

The reviewers and editor requested clarification of the role of Prdx6 in satellite cells ageing in addition to its characterisation as miR-24 target gene. We have now repeated all the experiments performed in the first version of this manuscript using miR-24 mimic and inhibitor with the addition of another condition: cell transfected with Prdx6 siRNA. Several key reagents, such as miR-24 inhibitor or Prdx6 siRNA have been discontinued (indicated in supplementary data) since we collected original data, therefore we decided to repeat all experiments.

All statistical analyses have been performed on raw values; T test have only been used for pairwise comparison if data was deemed normally distributed, otherwise Mann Whitney test was used. For multiple comparisons, we used One Way A.N.O.V.A followed by Tukey's multiple comparison or Kruskal Wallis test followed by Dunn's multiple comparison, as indicated in the figures.

We are happy to note that between the two different experimental settings and two sets of different reagents: miR-24, AM24 and siPrdx6, all data is consistent in terms of the phenotype elucidated by miR-24 and Prdx6. We included original data in the supplementary figures for the purpose of transparency and further support of the conclusions.

We believe the differences in the senescence phenotype between adult and old cells in the original data may results from a wide range of ages of mice used for myogenic progenitor isolation, e.g. cells from adult mice were isolated from mice 1-8 months old and cells from old mice were isolated from mice aged 20-24 months old. These ages are associated with dynamic changes in muscle, therefore we isolated myogenic progenitors from mice aged 6 (adult) or 24 (old) months old mice for the experiments contained within the revised manuscript.

The phenotype presented in the revised manuscript is consistent between adult and old cells with miR-24 having a more pronounced effects in cells from old mice; this is not entirely surprising as miR-24 has been previously shown to regulate senescence- and cell cycle associated genes which are dysregulated during ageing (please see page 9, discussion). Moreover, our data presented in the revised manuscript clearly demonstrate that downregulation of miR-24 target gene, Prdx6, is associated with disrupted mitochondrial morphology, increased mitochondrial ROS generation, increase in the levels of DNA damage marker: phosphorylated H2AX and consequently decreased cell viability, myogenic potential and increased senescence. In addition to determining the role of Prdx6 in satellite cells during ageing, we propose a mechanism by which miR-24 and Prdx6 changing

levels regulate ROS homeostasis and cell viability, senescence and myogenic potential during ageing. Please see below for the detailed response to the reviewer comments.

In addition, both reviewers ask for clarification and additional experiments solidifying the data regarding ROS and the regulation of ROS by miR24 and Prdx6. The supervising editor agrees with the reviewers' assessments and believes that additional data supporting a role for Prdx6 in regulating senescence would support the conclusions as no effects of Prdx6 manipulation on satellite cell senescence were provided.

Thank you for this suggestion. We have repeated all the previous cell experiments presented in the original manuscript using young and old mouse myogenic progenitors and human myogenic progenitors, treated with either scrambled control, miR-24, antagomiR-24 but also including an additional group with siPrdx6 to further elucidate the role of Prdx6 in myogenic progenitor viability, myogenic potential and senescence. These results are further complimented with additional experimentation including detection of mitochondrial ROS using Mitosox Red, quantification of DNA damage repair through immunostaining for phosphorylated H2AX, Western blots for Prdx6, Westerns for another mitochondrial peroxidase Prdx3 and the chaperone protein Hsp70.

#### Reviewer 1

Thank you for the invitation to review "miR-24: Prdx6 interactions regulate oxidative stress and viability of myogenic progenitors during aging" by Soriano-Arroquia et al. In this manuscript the authors provide mechanistic insight, spanning cells models, animal models and primary human tissue, to the interaction of miR24 and peroxiredoxin-6 and satellite cell function in the context of skeletal muscle ageing. The manuscript is very well written, and provides unique insight into the molecular regulators of satellite cell senescence during ageing. Further the evaluation of miRs as molecular regulators of redox biology is an emerging area, of interest to a wide readership.

Thank you for this comment, we agree that the manuscript presents novel data relevant to both microRNA and ageing fields.

This manuscript would likely garner attention from miRNA researchers outside of the muscle field. Thus, I feel the BaCl2 experiments needs a little more information and perhaps justification, to provide context in the type and magnitude of injury induced by this model and its applicability to studying muscle ageing. If the authors have any tangible data (perhaps included in the supplementary figures), then I think this could be a useful addition.

Thank you for this suggestion. Local injections with Barium Chloride (BaCl<sub>2</sub>) is a widely used model of skeletal muscle injury, established decades ago for the study of muscle generation and repair *in vivo* (Cerri et al. 2008, Kim et al. 2016). This model has been used by many researchers since it relatively inexpensive but an elegant approach, also comparable to other conventional acute injury models such as cardiotoxin (Hardy et al. 2016, Jung et al. 2019). Particularly, local muscle injury with BaCl<sub>2</sub> has been shown to induce depolarization of the sarcolemma, membrane rupture, proteolysis and motor denervation in the skeletal muscle fibers (Morton et al. 2019). However, BaCl2- induced muscle damage preserves satellite cells allowing for detailed study of their role in muscle regeneration (Morton et al., 2019). Through a straightforward intramuscular injection, a significant proportion of muscle is damaged and the regeneration follows through infiltration of immune cells, satellite cells activation with most of the damage resolved by 21 days in adult mice. However, in old mice, this damage is not resolved within 21 days, therefore this model is considered appropriate for studying changes in muscle regeneration during ageing (Fig. 1K). Representative images have been now included in the revised manuscript in Fig. 1K.

Aging Cell Page 4 of 50

#### **References:**

Cerri, D. G., L. C. Rodrigues, S. R. Stowell, D. D. Araujo, M. C. Coelho, S. R. Oliveira, J. C. S. Bizario, R. D. Cummings, M. Dias-Baruffi and M. C. R. Costa (2008). "Degeneration of dystrophic or injured skeletal muscles induces high expression of Galectin-1." Glycobiology **18**(11): 842-850. Hardy, D., A. Besnard, M. Latil, G. Jouvion, D. Briand, C. Thépenier, Q. Pascal, A. Guguin, B. Gayraud-Morel, J.-M. Cavaillon, S. Tajbakhsh, P. Rocheteau and F. Chrétien (2016). "Comparative Study of Injury Models for Studying Muscle Regeneration in Mice." PLOS ONE **11**(1): e0147198. Jung, H.-W., J.-H. Choi, T. Jo, H. Shin and J. M. Suh (2019). "Systemic and Local Phenotypes of Barium Chloride Induced Skeletal Muscle Injury in Mice." Annals of geriatric medicine and research **23**(2): 83-89.

Kim, J. H., G. C. Han, J. Y. Seo, I. Park, W. Park, H. W. Jeong, S. H. Lee, S. H. Bae, J. Seong, M. K. Yum, S. H. Hann, Y. G. Kwon, D. Seo, M. H. Choi and Y. Y. Kong (2016). "Sex hormones establish a reserve pool of adult muscle stem cells." <u>Nat Cell Biol</u> **18**(9): 930-940.

Morton, A. B., C. E. Norton, N. L. Jacobsen, C. A. Fernando, D. D. W. Cornelison and S. S. Segal (2019). "Barium chloride injures myofibers through calcium-induced proteolysis with fragmentation of motor nerves and microvessels." Skelet Muscle **9**(1): 27.

I was particularly interested in the mooted role of modified ROS generation in this model; however, I am not clear on the rationale of the experimental design – in the context of spiking the samples with hydrogen peroxide. Given the modified satellite cell function observed during ageing, I would have expected the authors to measure ROS using the typical family of fluorescent probes. Could the authors please clarify further (or more explicitly) why they chose to introduce hydrogen peroxide (mimicking oxidative stress), rather than measure endogenous ROS generation in their model, in the absence of H2O2?

The reviewer has made a good point, DCFH-DA is quite unspecific in terms of a measure of overall ROS and some of the chemistry is not fully understood. As mentioned we have repeated all previous experiments using primary mouse (young and old) and human myoblasts treated with miR-24 or antiiR-24 but have also included a group treated with siPrdx6 in the revised manuscript. Since Prdx6 has been previously shown to regulate mitochondrial ROS generation, we have focused on the measurement of MitoSox Red as an indicator of mitochondrial generated superoxide (Figs. 3F,H, 6C,F). In addition, we stained the mitochondria with Mitotracker Red to visualise their morphology (Figs. 3E, 6C).

Following on from my prior point, do the author have any gauge on whether markers of oxidative damage follow the trend they observed in CA-DCFH-DA fluorescence?

This is an excellent suggestion by the reviewer and we have now included a quantification of markers of DNA damage (H2AX) to compliment the increase in Mitosox in miR-24 and siPrdx6 treated cells, coupled with the increase in senescent cells. We have also included in the revised manuscript images of mitochondrial networks in these cells visualised using MitoTracker Red and have included Western blots analyses of the expression of Prdx6 and Prdx3 in young and old mouse primary myoblasts and human primary myoblasts (Fig3.E-H and Fig4.F-G). We found that consistent with the original data and Prdx6 downregulation resulted in altered morphology of mitochondrial networks, increased mitochondrial ROS generation and increase in DNA damage marker, however this was not associated with increase in PRDX3 levels (Figs.3,6). Interestingly, inhibition of miR-24 and downregulation of Prdx6 had an effect on HSP70 levels, which was different between cells from adult and old mice, which may provide further clarification on the more pronounced phenotype elucidated by miR-24 in cells from old mice (Fig. 4F,G).

Further, can the authors clarify the use of the DCFH-DA probe over other fluorescent probes? I am aware this is mentioned as a limitation; however, I feel the choice needs justification. I take a very pragmatic view on this, since there is not necessarily always an adequate choice, with many of the tools we used to measure ROS indirectly, have their own limitations.

**Aging Cell** 

The reviewer has made an excellent point and we agree that the original experiment in which cells were treated with H2O2, likely masking the effect of miR-24 and Prdx6, as well as using an unspecific ROS probe, was not very informative. Therefore, as mentioned previously in the revised manuscript where we have repeated all work on mouse and human primary myoblasts to include the siPrdx6 group, we have used Mitosox as an indicator of mitochondrial superoxide generation (Figs. 3F,H, 6C,F).

In some instances, modulation of specific antioxidant defence enzymes can invoke compensatory changes in others. Do the authors have any insight as to whether siRNA suppression of Prdx6 induced any compensatory responses in other systems.

Again this is an excellent point and we have analysed the expression of Prdx3, Hsp70 and SOD1 along with Prdx6, key antioxidant and chaperone proteins within the cell. On the protein levels, we consistently detected downregulation of PRDX6 in myogenic progenitors from adult and old mice, however the variability between the experimental groups was high and this is reflected throughout manuscript. Nevertheless, we are confident with the data as the phenotype elucidated by miR-24 and siPrdx6 was consistent between different assays used and between experiments performed in the original and revised manuscripts, both performed using different sets of reagents (due to discontinuation of miR-24 antimiR, control RNA and siRNA Prdx6 used in the original manuscript). We detected significantly decreased expression of Prdx6 in human primary myoblasts (Fig.6G) and adult myoblast treated with siPrdx6 but this did not reach significance in old primary myoblasts. This was associated with no change in PRDX3 or SOD1 levels and an increase in the expression of the chaperone protein HSP70 in primary myoblasts from adult but not old mice (Fig.4F,G, S6). These data suggest a potential mechanism by which miR-24:Prdx6 interactions may regulate cell senescence more robustly in the cells from old mice.

The authors use siRNA to supress Prdx6 expression in several experiments, could you please provide some information on the knockdown efficiency of your models?

The efficiency of the siPrdx6 was much more effective in human primary myoblasts with a very clear decrease in protein expression (~25%) (Fig. 6G). The change in expression of Prdx6 following siRNA in primary myoblasts from mice was ~50%, that reached significance in young but not old cells. We have repeated these experiments multiple times and the variability in the efficiency of transfections is quite high using siRNA as compared to miR mimic or antimiRs (Figs. 4. D,E,F,G, S2).

Similarly, could you provide some quantitative measure of transfection efficiency across all experiments?

In addition to the transfection efficiency observed when using siPrdx6 above, for 100nM miR mimic and antimiR, we observe >50% transfection efficiency in myoblasts as determined by fluorescently-labelled control mimics. However, we optimise the concentration of miR mimic or antagomiR based on significant up- or downregulation of miR, respectively. We aim for 2-fold increase or reduction in expression. These data are shown in Fig.S2.

#### Reviewer 2

In this paper the authors identify miR-24 as a potential regulator of factors involved in oxidative stress in satellite cells. The use a range of studies to examine the expression of miR-24 in muscle and in sorted muscle satellite cells from old and young mice. They identify miR-24 as differentially expressed between satellite cells from old and young mice. They examine the effects of both the miRNA and its antagomiR (AM24) on cell viability and on myotube formation. In old cells miR-24 reduces senescence and in adult cells AM24 reduces senescence. The gene expression data presented alongside are a little difficult to interpret as there is an increase in senescence markers in the adult cells in response to miR-24 but a reduction in old cells. Whether this is a consequence of the relative proportions of already senescing cells in the two different populations is difficult to know. The they show miR-24 can target Prdx6 and they examine the ability of miR-24 and AM24 to regulate Prdx6 mRNA and ROS. Finally they look at the effects of the miR and antagomiR in human cells on the same parameters. Overall, I find the data a little confusing as there are different (and sometimes opposing) effects of miR-24 and AM24 dependent on the age of the cells. If this is the case it is essential to pin down the real reasons and I am not sure that they manage this in the paper as presented. In particular they try to reason that Prdx6 is the key and I am not convinced that they succeed (see major point 3).

We would like to thank the reviewer for their comments and agree with the reviewer that the results were not always clear in the original submitted manuscript. We have repeated all the cell work using primary myoblasts from humans and mice to include a group with siPrdx6. We believe the data presented in the revised manuscript is a lot cleaner and supports our previous results on the role of Prdx6 in senescent cells.

Specifically, we further explored the role of miR-24 on senescence and optimised our experiment. As discussed in the manuscript, page 9:

According to published data, miR-24 regulates the expression of tumour suppressor/senescence-associated proteins differently depending on the cell type and metabolic state of the cell: it reduced P16 protein levels in human diploid fibroblasts and cervical carcinoma cells and it inhibited H2Ax in terminally differentiated hematopoietic cells making them vulnerable to DNA damage (Lal et al., 2009). On the other hand, miR-24 has been shown to increase p53 and p21 protein levels in different cancer cell lines (Mishra et al., 2009); and to induce p53 expression in human epithelial cells during aging and oxidative stress (Lu et al., 2018). Together, these results suggest that miR-24 exerts either an inhibitory or enhancer function over tumour suppressor/senescence-associated proteins depending on the cell cycle state, which is consistent with our findings. Context-dependent role of miRs has been previously demonstrated, as well as their dose-dependent regulation of physiological processes (Vasudevan, 2012).

As mentioned above, miR-24 targets several genes associated with cellular senescence and we agree with the reviewer that Prdx6 is, although important, is one of many physiologically relevant miR-24 targets. However, the date consistently indicate similarities between miR-24 overexpression and Prdx6 downregulation phenotypes. We agree that AM24 had limited effect on cellular senescence. This may be because the cells entered an irreversible senescence or the effect was not strong enough to be detected (Figs. 3A, 6A). Nevertheless, AM24 clearly promoted cell survival and myogenic differentiation (Figs. 2, 5).

miR-24 may have a different role on regulating cell cycle-associated genes depending on their cell cycle status as indicated by the acute increase in expression following muscle injury in adult mice (Fig. 1J). In the original manuscript, we used late passage cells with populations of approximately

50% cells showing replicative senescence. Moreover, the cells used were from a wide range of mice (adult 1-8 months old and old 20-24 months old). As dynamic changes occur in muscle during these ages, we optimised our approach in the revised manuscript and used cells at P4-P7 for all assays and cells from 6 (adult) or 24 (old) months old mice. Whilst miR-24 had a stronger effect on cells from old mice, the phenotypic effects were the same between cells from adult and old mice: miR-24 upregulation, as well as downregulation of its target Prdx6, was in all cases associated with an increase in cell senescence, as well as increased ROS generation and increase in the marker of DNA damage.

Moreover, we have explored further how miR24:Prdx6 may regulate cell viability, myogenic potential and senescence during ageing. Through exploring mitochondrial network morphology and ROS generation, as well as maker of DNA damage and changes in the levels of senescence (p16, p53). We believe that the data support the role of miR-24:Prdx6 in regulating viability and senescence pathways through increase in ROS generation and DNA damage which is associated with changes in viability and senescence upon miR-24 upregulation and downregulation of Prdx3. This is now discussed in the revised manuscript.

The authors claim in that the number of satellite cells goes down, the figure says % these are not necessarily the same thing as there could be an increase in fibroblasts or inflammatory cells in the old for the same number of satellite cells and that would give the same result.

Raw numbers would not provide a realistic interpretation of the data since the starting material (amount of muscle collected), as well as technical variabilities during the different FACS performed (such as longer sorting times), will affect the total number of cells sorted. We show in our FACS results that the % of satellite cells over the total number of cells decreases in the old mice compared to the adult mice. However, the results demonstrated in this manuscript are consistent with previously published data on decrease in satellite cell number during ageing (e.g. Snow et al, The effcts of aging on satellite cells in skeletal msucles of mice and rats; Cell Tissue Res, 1977; Verdijk et al., Reduced satellite cell numbers with spinal cord injury and aging in humans; Med Sci Sports Exerc, 2012).

Normalisation of data and use of t-Tests. I am a little concerned about the use of t-tests for data that has been normalised to 1 to allow the comparison of replicate experiments. Whilst it is common practice, I am not sure that it is correct. The t-test requires a normal distribution and this approach normally violates it in 2 ways. Firstly, the value 1 has no distribution so cannot be said to have a normal distribution and secondly the ratios are often not normally distributed because a two-fold reduction produces 0.5 whereas a two-fold increase is 2. If you use this approach to random data it is easy to generate a statistically significant increase with just noise. I realise that many of the differences observed are decreases but the point still stands. There needs to be a variance on the normalised value for a t-test to be applicable.

We agree with the reviewer. We originally normalised the data as described above, the variability of the control cell phenotype was high, most likely due to the wide range of ages of mice used to isolate myogenic progenitors. In the revised manuscript, all data collection has been repeated using 6- and 24-month mice and cells.

All statistical analyses have been performed on raw values; this information is contained within each figure legend. T test have only been used for pairwise comparison if data was deemed normally distributed, otherwise Mann Whitney test was used. For multiple comparisons, we used One Way A.N.O.V.A followed by Tukey's multiple comparison or Kruskal Wallis test followed by Dunn's multiple comparison, as indicated in the figures.

We are happy to note that between the two different experimental settings and two sets of different reagents: miR-24, AM24 and siPrdx6, all data is consistent in terms of the phenotype

induced by miR-24 and Prdx6. We included original data in the supplementary figures for the purpose of transparency and further support of the conclusions.

I am not sure that the miR-AM24 data really support the suggestion that the miRNA targets Prdx6 to increase oxidative stress. The data in Fig 4 show that there is more PrdX6 in cells from old mice(A), that there is a potential target site in the 3'-UTR (B) and that this site is targeted by miR-24 (C). However, any suppression of Prdx6 mRNA by additional miR-24 is small and only seen in old mice and there is no real effect of the AM24 (D/E). There is no western blot data to show reduced protein (which may have a larger effect).

We have analysed the expression of Prdx3, Hsp70 and SOD1 along with Prdx6, key antioxidant and chaperone proteins within the cell. On the protein levels, we consistently detected downregulation of PRDX6 in myogenic progenitors from adult and old mice, however the variability between the experimental groups was high and this is reflected throughout manuscript. Nevertheless, we are confident with the data as the phenotype elucidated by miR-24 was consistent between different assays used and between experiments performed in the original and revised manuscripts, both performed using different sets of reagents (due to discontinuation of miR-24 antimiR, control RNA and siRNA Prdx6 used in the original manuscript).

We detected a significant decreased expression of Prdx6 in human primary myoblasts (Figs. 4F,G, 6G) and adult myoblast treated with siPrdx6 but this did not reach significance in old primary myoblasts. This was associated with no change in PRDX3 or SOD1 levels and an increase in the expression of the chaperone protein HSP70 in primary myoblasts from adult but not old mice (Figs. 4F,G, 6G, S6). These data suggest a potential mechanism by which miR-24:Prdx6 interactions may regulate cell senescence more robustly in the cells from old mice.

The data in F, G and H are suggested to show changes in ROS production in the presence of H2O2. However, the size of the difference in the oxidative stress markers following transfection seems very small. Given the data are normalised to 1 the increase is 2.5%. The images also show a much larger apparent difference but the difference is restricted to what look like cells in clumps so it would be useful to see brightfield images to accompany the fluorescent images. Finally, I am not sure that the data in G and H really support the conclusion that is drawn.

In young mice there are no significant differences, whereas there are some differences in the old mice. The argument given is that there is more miR-24 in the young mice therefore less Prdx6 (Figs 1H and 4A). Consequently, if miR-24 was a major contributor to the reduction in Prdx6 then the AM24 should have a larger effect in the young mice than in the old but this doesn't happen, indeed there is no effect of the AM24 in the young mice. Similarly, as the amount of ROS precursor (H2O2) added is the same and there should be more Prdx6 in the old cells then if Prdx6 was the major regulator of oxidative stress in the system then there should be greater ROS production in the young mouse samples (due to less Prdx6) than in the old mouse samples but from the images this isn't the case.

Furthermore, the significant differences for miR-24 in the old mice are between transfection with miR-24 and transfection with the AM24 and not between either and the control. The argument here is that the levels of miR-24 are low so there is no effect of the AM24. However, as the levels of Prdx6 are very high there ought to be a significant effect of the miR and there isn't.

Furthermore, knockdown of Prdx6 increases ROS (siRNA data) but this increase is suppressed by addition of the AM24. As Prdx6 has been knocked down by an siRNA how can the effects of the AM24 on ROS be via Prdx6 as there is no Prdx6 for miR-24 to be suppressing so no effect for the AM24 to reverse. Any effect of the AM24/miR would have to be by targeting a separate component of the ROS pathway or an indirect effect on Prdx6 expression (though this seems to be ruled out by Fig 4D/E). This later argument also applies to the data in Fig 6B where again the AM24 reverses the effect of the siRNA.

As reviewer 1 commented, DCFH-DA is quite unspecific in terms of a measure of overall ROS and some of the chemistry is not fully understood. As mentioned above, we have repeated all previous experiments using primary mouse (young and old) and human myoblasts treated with miR-24 or antagomiR-24 but have also included a group treated with siPrdx6 in the revised manuscript. Since Prdx6 has been previously shown to regulate mitochondrial ROS generation, we have focused on the measurement of MitoSox Red as an indicator of mitochondrial generated superoxide. In addition, we stained the mitochondria with Mitotracker Red to visualise their morphology (Figs. 3E,F,H, 6C,D,F). We did not treat the cells with H2O2 as indicated in Figure S5, treatment of H2O2 produces a massive induction of ROS generation, which was likely masking the effects of miR-24 and Prdx6 in the original manuscript.

We believe that the more pronounced effects of miR-24 in cells from old mice are the result of miR-24 regulating other genes, such as p21, and not due to different levels of Prdx6 between adult and old cells (please see page 9 discussion and above) — we would like to thank the reviewer for pointing this out.

Reviewer is correct and there are multiple possible pathways through which Prdx6 can exert its effects, as Prdx6 has a number of known functions as a peroxidase and phospholipase activities, indeed the latter of which can potentially promote ROS production via its role in the activation of Nox2. The data presented in the revised manuscript would confirm our original hypothesis that Prdx6 has a key role in senescence via the increase in ROS generation and overall DNA damage. Nevertheless, we acknowledge this limitation of our data in the revised manuscript (page 10): Moreover, the diverse activities of Prdx6, including peroxidase, PLA2 phospholipase and LPCAT activities, mean that it could potentially regulate different metabolic signalling pathways, from cell cycle, membrane repair and antioxidant response (Arevalo & Vázquez-Medina, 2018; López Grueso et al., 2019). The limitation of this manuscript is that it did not explore the function of Prdx6 as PLA2 phospholipase in the context of muscle ageing.

Line 177: position 2-6 (6mer): should be 5mer

Thank you, this has been corrected.

Aging Cell Page 10 of 50

### AGING CELL AUTHOR CHECKLIST. Authors should submit this checklist together with their manuscript. Please ensure that you have read the Author Guidelines in detail before submission.

| Title   | miR-24 and its target gene Prdx6 regulate viability and   |           |                       |                            |                             |  |   |
|---|---|-----------|-----------------------|----------------------------|-----------------------------|--|---|
|   | senescence of myogenic progenitors during aging   |           |                       |                            |                             |  |   |
| Authors   | Ana Soriano-Arroquia, John Gostage, Qin Xia, David Bardell, Rachel McCormick, Eugene McCloskey, Ilaria Bellantuono, Peter Clegg, Brian McDonagh, Katarzyna Goljanek-Whysall |           |                       |                            |                             |  |   |
| <b>1</b>  |   |           |                       |                            |                             |  |   |
| Manuscript Type   | Research Report   |           |                       |                            |                             |  |   |
| Total Character<br>Count (including<br>spaces) <sup>1</sup>                   | 47,158  |           |                       |                            |                             |  |   |
| Word count of Summary <sup>2</sup>  | 247   |           |                       |                            |                             |  |   |
| Number of papers<br>cited in the<br>References <sup>3</sup>                   | 45  |           |                       |                            |                             |  |   |
| Listing of all Tables (Table1, Table 2 etc)4                                  | Table S1, Table S2  |           |                       |                            |                             |  |   |
|   |   |           |                       |                            |                             |  |   |
| Figure specifications<br>(please complete<br>one row per figure) <sup>5</sup> | Colour  | Greyscale | Black<br>and<br>white | Single<br>column<br>(80mm) | Double<br>column<br>(167mm) | Size of figure at full scale (mm x mm)  (insert details) | Smallest font size used in the figure at full scale (minimum 6pt) (insert |
| Figure no.  | (yes/no)  | (yes/no)  | (yes/no)              | (yes/no)                   | (yes/no)                    | ,  | details)  |
| 1   | Yes   | No        | No                    | No                         | Yes                         | 160x204  | 6pt   |
| 2   | Yes   | No        | No                    | No                         | yes                         | 150x175  | 6pt   |
| 3   | Yes   | No        | No                    | No                         | yes                         | 160x228  | 6pt   |
| 4   | Yes   | No        | No                    | No                         | Yes                         | 160x165  | 6pt   |
| 5   | Yes   | No        | No                    | No                         | Yes                         | 152x91   | 6pt   |
| 6   | Yes   | No        | No                    | No                         | Yes                         | 137x112  | 6pt   |
| Supplementary 1   | Yes   | No        | No                    | No                         | Yes                         | 194.5x162.7  | 6pt   |
| Supplementary 2   | Yes   | No        | No                    | No                         | Yes                         |  | 6pt   |

| Supplementary 3    | Yes | No | No | No  | Yes | 160x131 | 6pt |
|--------------------|-----|----|----|-----|-----|---------|-----|
| Supplementary 4    | Yes | No | No | Yes | No  | 160x150 | 6pt |
| Supplementary 5    | Yes | No | No | Yes | No  | 76x124  | 6pt |
| Supplementary 6    | Yes | No | No | Yes | No  | 94x120  | 6pt |
| Graphical abstract | Yes | No | No | Yes | No  | 50x60   | 6pt |

<sup>&</sup>lt;sup>1</sup> The maximum character count allowed is 50,000 (incl. spaces) for Primary Research Papers, 10,000 for Short Takes and 20,000 for Reviews.

<sup>&</sup>lt;sup>2</sup> Summary should not exceed 250 words.

<sup>&</sup>lt;sup>3</sup> Primary Research Papers can contain a maximum of two tables. If more are needed they should replace some of the Figures or can be placed in the Supporting Information.

<sup>&</sup>lt;sup>4</sup> A maximum of 45 references is allowed for Primary Research Papers and 20 references for Short Takes.

for a up to the size they are <sup>5</sup> A Primary Research Paper may contain up to 6 figures and a Short Take up to 2 figures. Authors are encouraged to provide figures in the size they are to appear in the journal and at the specifications given.

### miR-24 and its target gene Prdx6 regulate viability and senescence of

| 2        |        | myogenic progenitors during aging   |
|----------|--------|---|
| 3        | Ana S  | Soriano-Arroquia <sup>1,2*</sup> , John Gostage <sup>2, 3,4*</sup> , Qin Xia <sup>3</sup> , David Bardell <sup>1,2</sup> , Rachel McCormick <sup>1,2</sup> , Eugene |
| 4<br>5   | McCl   | loskey <sup>2,4</sup> , Ilaria Bellantuono <sup>2,4</sup> , Peter Clegg <sup>1,2</sup> , Brian McDonagh <sup>3</sup> , Katarzyna Goljanek-Whysall <sup>1, 2,3</sup> |
| 6        | 1- In  | stitute of Life Course and Medical Sciences, University of Liverpool  |
| 7        | 2- Th  | ne Medical Research Council / Versus Arthritis Centre for Integrated Research into  |
| 8        | M      | lusculoskeletal Aging; CIMA. University of Liverpool. William Henry Duncan Building. 6 West   |
| 9        | De     | erby Street, Liverpool L7 8TX, UK   |
| 10       | 3- Di  | iscipline of Physiology, School of Medicine, National University of Ireland Galway, Ireland   |
| 11       | 4- H   | ealthy Lifespan Institute and The Centre for Integrated Research in Musculoskeletal Aging,  |
| 12       | De     | epartment of Oncology and Metabolism, University of Sheffield, Sheffield, UK  |
| 13       | *_     | these authors contributed equally   |
| 14       |        |   |
| 15       | Corre  | spondence:  |
| 16       | Katarz | zyna Goljanek-Whysall; Institute of Life Course and Medical Sciences, University of Liverpool and   |
| 17       | Discip | line of Physiology, School of Medicine, National University of Ireland Galway, Ireland  |
| 18       |        |   |
| 19       | e-mai  | l: k.whysall@liverpool.ac.uk; kasia.whysall@nuiglaway.ie  |
| 20       |        |   |
| 21<br>22 | Runni  | ng title: miR-24 in muscle regeneration during aging  |
| 23       |        |   |
| 24       |        |   |
| 25       |        |   |
| 26       |        |   |
| 27       |        |   |
| 28       |        |   |
| 29       |        |   |
| 30       |        |   |
| 31       | Keyw   | ords: miR-24, Prdx6, aging, muscle regeneration, satellite cells, oxidative stress, senescence  |
| 32       |        |   |
| 33       |        |   |

#### **GRAPHICAL ABSTRACT**

Age-related changes in miR-24 and its target gene Prdx6 contribute to defective function of myogenic progenitors and muscle regeneration during aging. miR-24 upregulation and downregulation of its target Prdx6 is associated with an increase in mitochondrial ROS, increase in pH2Ax, decreased cell viability, myogenic potential and increased senescence. During aging, downregulation of miR-24 in satellite cells and after muscle injury may represent a compensatory mechanism acting to preserve cell viability and myogenic potential.

#### ABSTRACT

Satellite cell-dependent skeletal muscle regeneration declines during aging. Disruptions within the satellite cells and their niche, together with alterations in the myofibrillar environment contribute to age-related dysfunction and defective muscle regeneration.

In this study, we demonstrated an age-related decline in satellite cell viability and myogenic potential, and an increase in ROS and cellular senescence. We detected a transient upregulation of miR-24 in regenerating muscle from adult mice and downregulation of miR-24 during muscle regeneration in old mice. FACS-sorted satellite cells were characterised by decreased levels of miR-24 and a concomitant increase in expression of its target: Prdx6. Using GFP reporter constructs, we demonstrated that miR-24 directly binds to its predicted site within Prdx6 mRNA. Subtle changes in Prdx6 levels following changes in miR-24 expression indicate miR-24 plays a role in fine-tuning Prdx6 expression. Changes in miR-24 and Prdx6 levels were associated with altered mitochondrial ROS generation, increase in the DNA damage marker: phosphorylated-H2Ax and changes in viability, senescence and myogenic potential of myogenic progenitors from mice and humans. The effects of miR-24 were more pronounced in myogenic progenitors from old mice, suggesting a context-dependent role of miR-24 in these cells, with miR-24 downregulation likely a part of a compensatory response to decline in cell function during aging.

We propose that downregulation of miR-24 and subsequent upregulation of Prdx6 in muscle of old mice following injury is an adaptive response to aging, to maintain satellite cell viability and myogenic potential through regulation of mitochondrial ROS and DNA damage pathways.

#### INTRODUCTION

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

The regenerative capacity of skeletal muscle facilitates a high plasticity for adaptation to diverse metabolic conditions and energetic demands. Skeletal muscle regeneration after injury and loading stressors relies on satellite cells, the adult muscle stem cells able to regenerate muscle fibres in vivo. A balance between satellite cells self-renewal and myogenic differentiation is essential for successful muscle regeneration after injury (Sambasivan & Tajbakhsh 2015). However, the effectiveness of muscle regeneration throughout lifespan not only relies on the functionality of satellite cells (Lepper et al. 2011), but also other factors, such as disrupted intracellular signalling and an altered muscle fibre microenvironment are known to play a key role in muscle wasting during disuse, ageing and chronic diseases (Fry et al. 2015; Le Moal et al. 2017). In particular, oxidative stress has been demonstrated to alter the cellular microenvironment, resulting in disrupted cellular signalling and potentially oxidative modifications of muscle contractile proteins (Goljanek-Whysall et al. 2016; Sakellariou et al. 2017). Some of the important muscle antioxidant proteins that directly affect intracellular ROS concentrations are members of the peroxiredoxin family: (PRDX1-PRDX6). Peroxiredoxins have the capacity to regulate redox homeostasis and signalling pathways involved in processes such as apoptosis and cell survival or in response to injury. Particularly, Peroxiredoxin 6 (Prdx6) has been demonstrated to regulate both myogenesis and adipogenesis via the control of glucose uptake (Pacifici et al. 2014; Wu et al. 2015), and Prdx6-/- mice display increased levels of markers of senescence, metabolic sarcopenia and loss of muscle strength (Pacifici et al. 2020).

86 87

88

89

90

91

92

93

94

microRNAs (miRNAs, miRs) are short non-coding RNAs approximately 20-22 nucleotides in length. miRs show partial complementarity to their target mRNA(s) and regulate gene expression at the post-transcriptional level (Lee *et al.* 1993). miRs are known to regulate a myriad of biological processes, including muscle homeostasis and aging through processes such as ROS generation and scavenging (Goljanek-Whysall *et al.* 2020). miR-24 is highly expressed in skeletal muscle (Wada *et al.* 2011) and has been proposed to regulate myogenesis *in vitro* and to inhibit muscle fibrosis *in vivo* (Sun *et al.* 2008; Sun *et al.* 2018). Yet, the functional role of miR-24 in human and mouse primary myogenic stem/progenitor cells, including oxidative stress, and in skeletal muscle aging remains elusive.

95 96

97

98

99

100

101

In this study, we identified changes in miR-24:Prdx6 interactions in satellite cells during aging. Our data confirm a decline in satellite cell fraction, viability and myogenic potential in muscle from old mice. miR-24 expression was downregulated in FACS-sorted satellite cells during aging, with the concomitant upregulation of its target Prdx6. Our results demonstrate a transient upregulation of miR-24 in regenerating muscle from adult mice after acute injury, whereas in old mice, we detected

103

104

105

106

107

108

109

110

111112

downregulation of miR-24 expression during muscle regeneration. Using GFP reporter constructs, we demonstrated the binding of miR-24 to its target site within Prdx6 mRNA. Changes in miR-24:Prdx6 interactions were associated with altered mitochondrial ROS generation and levels of phosphorylated-H2Ax in myogenic progenitors and affected their viability, myogenic potential and senescence. The effects of miR-24 up- and downregulation were more pronounced in myogenic progenitors from old mice, suggesting a context-dependent role of miR-24 in these cells. We propose that changes in miR-24:Prdx6 interactions during aging are aimed at preserving satellite cells viability and function. We hypothesise that age-related downregulation of miR-24 and subsequent increased Prdx6 expression in satellite cells represents an adaptive mechanism aimed to improve the regenerative capacity of skeletal muscle through preserving satellite cell viability and function by regulating ROS-associated pathways.

113

114

115

116

117118

119

120

121

122

123

124

125

126

127

128

129

130131

132

133

134

135

#### **RESULTS**

#### miR-24 is downregulated during skeletal muscle regeneration and aging

miR-24 has been previously shown to be regulated during satellite cell activation (Cheung et al. 2012; Redshaw et al. 2014). Some of the miR-24 putative targets in humans, analysed using TargetScan and ClueGO plugin for Cytoscape, were genes associated with the cellular response to oxidative stress, including Prdx6 (Figure 1A). We focused on miR-24 target genes associated regulation of viability, differentiation and senescence through regulation of redox balance, as redox homeostasis has been shown to regulate all these processes during aging (Le Moal et al. 2017). Prdx6 has been shown to regulate skeletal muscle adaptation under increased oxidative stress (Da Silva-Azevedo et al. 2009). Prdx6 was upregulated in FACS-sorted satellite cells isolated from old mice compared to adult mice (Figure 4A), but not in the tibialis anterior muscle from old mice (Figure S2). This is consistent with downregulation of miR-24 expression in satellite cells but not muscle during aging (Figure 1H, J). We therefore investigated age-related changes in miR-24:Prdx6 interactions in satellite cells. We observed a decrease in the total number of FACS-sorted satellite cells during aging (Figures 1B, S1), consistent with previously published data (Gibson & Schultz 1983). Myogenic progenitors from old mice displayed increased senescence (Figures 1C, 3A), reduced viability (Figures 1D, 2A), reduced myogenic potential (Figures 1E, 2D) and increased ROS (Figures 1F, 1G). miR-24 expression was downregulated in satellite cells from old mice (Figure 1H). The expression of miR-24 was also analysed by RT-qPCR in an in vivo model of skeletal muscle regeneration following barium chloride (BaCl<sub>2</sub>) injection (Figures 11, 11, 1K). Local muscle injury with BaCl<sub>2</sub> has been shown to induce depolarization of the sarcolemma, membrane rupture, proteolysis and motor denervation in the skeletal muscle fibers (Morton et al. 2019). However, BaCl2- induced muscle damage preserves satellite cells allowing for detailed study of

their role in muscle regeneration (Morton et al., 2019). Most of the damage resolved by 21 days in adult but not old mice, in which central nuclei remain after 21 days (Figure 1K). miR-24 basal levels were not altered in TA muscle during aging, as opposed to its downregulation in satellite cells (Figure 1H, 1J), but its expression was increased one day after muscle injury and returned to basal levels after seven days in the injured muscle of adult mice, suggesting a potential role of miR-24 in the early stages of muscle regeneration after acute injury. However, the expression of miR-24 did not increase in old mice following injury: miR-24 expression was significantly lower at 1-21 days after injury compared to the adult mice (Figure 1J). These data suggest that the downregulation of miR-24 in satellite cells (Figure 1H) may be related to the age-related decline in satellite function and consequently muscle regeneration following acute injury.

#### miR-24 regulates viability and myogenic potential of myogenic progenitors during aging

The function of satellite cells in muscle regeneration depends on their viability and myogenic potential, both are affected by aging (Figures 1D, 1E). To determine the physiological consequences of miR-24 and its target Prdx6 dysregulation in satellite cells during aging and regeneration, myogenic progenitors isolated from adult and old mice were transfected with miR-24 mimic, AM24, siRNA for Prdx6 or scrambled RNA (control) and stained to evaluate differentiation (MF 20), proliferation (Ki67) and viability (Figures 2, S4). miR-24 had no significant effect on myogenic progenitor proliferation (Figure S3). However, overexpression of miR-24 and downregulation of Prdx6 expression resulted in the increased proportion of necrotic and apoptotic myogenic progenitors from adult and old mice and inhibition of miR-24 resulted in an increase in the total number and number of viable myogenic progenitors (Figure 2A, B). Moreover, overexpression of miR-24 and downregulation of its target: Prdx6, in myogenic progenitors from adult and old mice resulted in inhibition of myogenesis (Figure 2C, D). These data were consistent with previous, independently performed analyses of miR-24 role in myogenic progenitors (Figure S3).

#### miR-24 and its target Prdx6 regulate senescence of myogenic progenitors.

Satellite cells have been previously shown to undergo senescence during aging (Blau *et al.* 2015; Zhu *et al.* 2019). Adult and old myogenic progenitors at passage 7, Senescent cells become present in both culture from adult and old myogenic progenitors from at passage 7, cells were then transfected with miR-24 mimic or inhibitor (AM24) or Prdx6 siRNA. Overexpression of miR-24 or Prdx6 downregulation led to a higher proportion of senescent cells in myogenic progenitors from both adult and old mice, as well as higher number of senescent cells as measured by SA- $\beta$ gal staining and by measurement of fluorescent SA- $\beta$ gal. (Figure 3A-C). The expression of senescence-associated genes p16 and p53 was not changed in myogenic progenitors from adult mice following miR-24 overexpression or Prdx6

downregulation (Figure 3D). In myogenic progenitors from old mice, miR-24 overexpression and downregulation of Prdx6 led to increased p16 and p53 levels, which were significantly different in cells treated with siRNA for Prdx6 (Figure 3D). However, inhibition of miR-24 in myogenic progenitors from old mice had no significant effect on number of SA-βgal positive cells or the overall proportion of senescent cells or expression of senescence-associated genes (Figure 3A-D). This could be associated with already low levels of miR-24 in cells from older mice or altered levels of other target genes of miR-24, such as p21 in myogenic progenitors from adult and old mice (Lal et al., 2009)(Mishra et al., 2009)(Lu et al., 2018). The latter is supported by our initial assessment of the role of miR-24 in regulating senescence of myogenic progenitors, where miR-24 had different effects on changes in senescence-associated gene expression in senescent cells from adult and old mice, despite similar effects on cellular senescence on the phenotypic level (Figure S3C,E).

## miR-24 and its target Prdx6 regulate mitochondrial ROS production and the levels of DNA damage marker.

As Prdx6 has been previously shown to regulate mitochondrial dynamics and function, myogenic progenitors cells transfected with miR-24, AM24 or Prdx6 siRNA and stained with MitoTracker Red to visualise mitochondria (Figure 3E), as well as Mitosox Red and phosphorylated H2Ax, to detect mitochondrial ROS and DNA damage, respectively (Figure 3E-H). Myogenic progenitors from both adult and old mice showed disrupted mitochondrial morphology, increased mitochondrial ROS production and increase in DNA damage marker following overexpression of miR-24 or downregulation of Prdx6 expression (Figure 3E-H). These effects were more pronounced in myogenic progenitors from old mice, consistent with the differences in regulation of senescence by miR-24 in myogenic progenitors from adult and old mice, suggesting a context-dependent function of miR-24. Together, these data indicate a potential mechanism of regulation of myogenic progenitor senescence and viability by miR-24 and its target Prdx6, where increased levels of miR-24 and concomitant downregulation of Prdx6 lead to disruption of mitochondrial morphology, increase in mitochondrial ROS production, increase in DNA damage marker levels and induction of pro-apoptotic and/or prosenescent pathways, likely through p16 and p53 signalling.

#### miR-24 directly regulates the expression of Prdx6 in myogenic progenitors

Prdx6 is a confirmed miR-24 target in human cells (Li *et al.* 2016). We next analysed the sequence of mouse Prdx6 for miR-24 binding sites. A target site for miR-24 was found between position 2-6 (5-mer) of the mature microRNA-24 and position 41-45 5'UTR of the mouse Prdx6-202 transcript (Figure 4B). A GFP reporter containing the wild type or mutated miR-24 binding site for miR-24 was generated (Figure 4C). C2C12 myoblasts were transfected with reporter constructs containing wild type or

mutated miR-24 binding site within the Prdx6 5'UTR fragment and co-transfected with miR-24 mimic or scrambled sequence (control). GFP levels were decreased in the cells transfected with wild type construct co-transfected with miR-24 as compared to scrambled treated cells, but not in the cells treated with the mutated construct co-transfected with miR-24 or control Scr microRNA These results confirm that miR-24 directly binds to Prdx6 mRNA in mouse myoblasts (Figure 4C). We next investigated Prdx6 expression following miR-24 overexpression or downregulation in myogenic progenitors from adult and old mice. Prdx6 expression was significantly downregulated following miR-24 overexpression in myogenic progenitors from old but not adult mice (Figure 4E). Similarly, protein levels of PRDX6 were affected by miR-24 levels in old but not adult mice, although these changes did not reach statistical significance, likely due to relatively small n number (n=3). Cell treated with Prdx6 siRNA showed lower levels of PRDX6, although the level of downregulation varied between individual replicates (Figure 3F,G). Interestingly, changes in the levels of miR-24 or Prdx6 did affect the levels of a mitochondrial peroxiredoxin PRDX3. However, inhibition of miR-24 or downregulation of Prdx6 levels resulted in changes in the levels of chaperone protein HSP70 in adult progenitors suggesting a potential mechanism underlying the phenotypic differences between the effects of miR-24 on myogenic progenitors from adult and old mice (Figure 4F,G).

# miR-24 regulation of myogenic potential and viability by controlling Prdx6 is conserved in human myogenic progenitors

We further explored whether the function of miR-24 and its target Prdx6 is conserved in human cells. Myogenic progenitors isolated from adults were transfected with miR-24 mimic, AM24, siRNA for Prdx6 or scrambled control. miR-24 overexpression and downregulation of Prdx6 expression resulted in decreased cell viability and lower total cell number as well as decreased myogenic potential with miR-24 overexpression and siPrdx6 downregulation resulting in the presence of smaller myotubes containing fewer nuclei (Figure 5A-D). miR-24 had no effect on proliferation of human myogenic progenitors (Figure S4), consistently with the lack of miR-24 regulation of murine cell proliferation. These data are consistent with murine data and our initial assessment of miR-24 role in human myogenic progenitors (Fig.S4 A,B).

229230

231

232

233

234

235

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

# miR-24 and its target Prdx6 regulate mitochondrial ROS production and senescence of human progenitors.

miR-24 overexpression and downregulation of Prdx6 expression both led to an increased number of senescent cells (Figure 6A, B) as compared to control group. To determine whether miR-24 and Prdx6 were involved in regulating ROS levels in human cells, primary myogenic progenitors were transfected with miR-24 mimic, anti-miR (AM24), siRNA against Prdx6 (siPrdx6) or scrambled control RNA (Scr)

(Figure 6). Similar to the results obtained from myogenic progenitors isolated from mice (Figure 4), disrupted mitochondrial morphology and increased mitochondrial ROS production were detected after miR-24 overexpression and Prdx6 silencing in comparison to scrambled control group (Figure 6C-F). In addition, miR-24 overexpression and Prdx6 silencing led to the presence of nuclei positive for phosphorylated H2Ax, a marker of DNA damage, however this increase did not reach statistical significance (Figure 6E,F). Western blot analyses revealed downregulation of PRDX6 levels following miR-24 overexpression (not significant) and Prdx6 siRNA (significant), however no changes were detected in the levels of antioxidant protein PRDX6 (Figure 6G). Together, these data indicate that miR-24 and its target Prdx6 regulate the viability, senescence and myogenic potential through controlling pathways associated with mitochondrial ROS generation, DNA damage and potentially unfolded protein response (UPR) with the different effects of miR-24 and Prdx6 on the levels of HSP70 in myogenic progenitors from adult and old mice indicating a potential mechanism underlying the stronger effects of miR-24 on cells from old mice.

**Aging Cell** 

#### DISCUSSION

Muscle aging is associated with the disruption of a wide range of physiological processes affecting the myocyte niche, compromising satellite cell functionality and their regenerative potential in response to injury (Sannicandro *et al.* 2019).

Following injury, an acute increase in endogenous ROS is required to promote a pro-inflammatory environment that helps with macrophage recruitment (Horn *et al.* 2017). ROS levels decrease at later stages of regeneration to allow muscle hypertrophy and remodelling (Laumonier & Menetrey 2016). However, this process must be tightly regulated, as chronically elevated ROS may induce irreversible protein modifications, aberrant signalling, DNA damage and mutagenesis (Kidane *et al.* 2014). When damage persists, cellular stressors can trigger a transient cell cycle arrest via activation of p53/p21 or p16/pRB axes, which can eventually result in the induction of cellular senescence or cell death programs such as apoptosis and autophagy (Vicencio *et al.* 2008).

This study aimed to investigate the underlying biological mechanisms of the microRNA miR-24-3p and its target gene Prdx6 in muscle regeneration during aging. Our results demonstrate a transient increase in miR-24 expression one day after acute injury in an *in vivo* model of skeletal muscle regeneration in adult mice. miR-24 expression returned to baseline levels 7 days after injury, when myoblasts stop proliferating and start differentiating to initiate tissue remodelling in mice (Grounds 2014). Similar to the results presented here, miR-24 expression is dynamically changed during gastric metastasis progression (Li *et al.* 2016). We have also identified an upregulation of the anti-oxidant Prdx6 in mouse quiescent satellite cells during aging, and confirmed Prdx6 as a direct target gene of

miR-24 in mice. However, changes in Prdx6 mRNA and protein levels were modest following miR-24 overexpression and inhibition (Figure 4), suggesting a fine-tuning rather than major regulator role of miR-24 in controlling the levels of PRDX6.

Our results suggest that downregulation of miR-24 in satellite cells and concomitant upregulation of its target gene Prdx6 is associated with disrupted mitochondrial network morphology, increased ROS generation, an increase in the levels of phosphorylated-H2AX, a marker of DNA damage, and on a phenotypic level, a decrease in cellular viability and myogenic potential, as well as increase in senescence of surviving cells. Interestingly, miR-24 has been previously shown to regulate senescenceassociated genes (Lal et al., 2009)(Mishra et al., 2009)(Lu et al., 2018).and our results also showed changes in the expression of p16, p21 and p53 in primary myogenic progenitors after miR-24 overexpression or Prdx6 downregulation (Figures 3D, S3). Whilst on a phenotypic level, changes in miR-24 levels consistently regulated cellular senescence, some differences were observed between cells which have or not undergone replicative senescence in culture (Figures 3, S3) and cells from adult and old mice (Figures 3, S3). The effects of Prdx6 downregulation on cell senescence were consistent in all cells suggesting that miR-24 may regulate cellular senescence through multiple targets in addition to Prdx6. For example, miR-24 has been shown to increase DNA damage through regulating the levels of H2AX protein or p21 (Lal et al., 2009). Moreover, according to published data, miR-24 regulates the expression of tumour suppressor/senescence-associated proteins differently depending on the cell type and metabolic state of the cell: it reduced p16 protein levels in human diploid fibroblasts and cervical carcinoma cells and it inhibited H2Ax in terminally differentiated hematopoietic cells making them vulnerable to DNA damage (Lal et al. 2009). On the other hand, miR-24 has been shown to increase p53 and p21 protein levels in different cancer cell lines (Mishra et al. 2009); and to induce p53 expression in human epithelial cells during aging and oxidative stress (Lu et al. 2018). Together, these results suggest that miR-24 exerts either an inhibitory or enhancer function over tumour suppressor/senescence-associated proteins depending on the cell cycle state, which is consistent with our findings. Context-dependent role of miRs has been previously demonstrated, as well as their dose-dependent regulation of physiological processes (Vasudevan 2012). Moreover, miR-24 may regulate the expression of senescence-regulated genes via an upstream regulatory factor not yet identified by us. The delicate balance between apoptotic, anti-apoptotic, proliferative and cell cycle arrest signals will ultimately determine whether some cells successfully differentiate/self-renew or, in contrast, die/become senescent.

301

270

271

272

273

274

275

276

277

278279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

304

305

306

307

308

309

310

311

312

313

314315

316

317

318

319

320

321

322

323

324

325

326

327328

329

330

331

332

333

334

Moreover, the diverse activities of Prdx6, including peroxidase, PLA2 phospholipase and LPCAT activities, mean that it could potentially regulate different metabolic signalling pathways, from cell cycle, membrane repair and antioxidant response (Arevalo & Vázquez-Medina 2018; López Grueso *et al.* 2019). One limitation of this manuscript is that it did not explore the function of Prdx6 as PLA2 phospholipase in the context of muscle muscle repair and ageing.

Another limitation of this study is the variability in the efficiency of the transfection experiments. For the qPCR experiments, only samples where transfection efficiency was validated, either by an increased or inhibited expression of miR-24, were taken into consideration for the quantification of the target gene expression. In particular, the inhibition of miR-24 was challenging to achieve despite using two different miR-24 inhibitors, which resulted in a reduced number of the independent replicates used for this particular group. Likewise, the efficiency in the transfection of the cells used for the immunofluorescence experiments might also be affected. Another limitation to be considered is the use of solely one technique for the assessment of ROS generation and oxidative stress. Future studies should corroborate these findings using additional approaches. Despite using two independent assays to detect cellular senescence, SA-β-gal results should be interpreted with caution, as increased intensity of the staining in some cells did not always correlate with an extension of the cytoplasm, which is a well-known characteristic of senescent cells. Therefore, SA-β-gal staining and higher levels of tumour suppressor proteins may not always indicate a permanent cell cycle arrest, but probably a stress-induced transient cell cycle arrest that might trigger alternative processes such as apoptosis or autophagy. This assumption fits well with our data, where miR-24 overexpression and Prdx6 downregulation lead to cell death and increased senescence. Alternatively, the cells overexpressing miR-24 or cells with downregulated levels of Prdx6 may enter irreversible senescence and the final post-senescent stage of cell death (Gamez et al., 2019). Cell senescence and cell death share common factors and both have been shown to be interdependent in certain scenarios (Gamez et al., 2019). Our data indicate that overexpression of miR-24 and downregulation of Prdx6 are associated with changes in mitochondrial morphology, increase in mitochondrial ROS generation and increased levels of phospho-H2Ax (Figures 3,6). It has been shown that following DNA damage, cells undergo a temporary cell cycle arrest in an attempt to repair their DNA; if the DNA damage is unresolved, cells can undergo apoptosis or become senescent; in case of increased damage in senescent cells, senescent cells may undergo cell death (Gamez et al., 2019).

Noteworthy, myogenic progenitors isolated from mouse were from males whereas human samples were retrieved from female donors. Several studies have shown biological differences between rodent males and females in the development of sarcopenia and efficiency in muscle regeneration, as well as in the global expression of microRNAs in human skeletal muscle (Maher *et al.* 2009; Kob *et al.* 2015). It is thus important to point out that the altered expression of genes in satellite cells and muscle progenitors shown in this study might be sex-specific in addition to species-associated differences.

In summary, our results identify a role for miR-24-3p through inhibition of Prdx6 in satellite cells during aging which may play a key role in early stages of skeletal muscle regeneration after acute injury, through controlling adaptive redox and apoptotic and senescence signalling pathways. Moreover, our findings show that miR-24 and Prdx6 regulation of myogenic progenitor phenotype is more pronounced in cells from old mice, likely due to miR-24 regulation of additional to Prdx6 target genes, such as p21. This mechanism may not be as strongly conserved in mice as in humans, as the effects of miR-24 regulated ROS, myoblast viability, differentiation and senescence was more pronounced in myoblasts from adult humans. This is not surprising, as miR-24 binding site in Prdx6 resides at the 3'UTR of the human Prdx6 transcript, whereas in mice, this site has a weaker interaction at the 5'UTR of the Prdx6 transcript. The role of miR-24 in the regulation of muscle regeneration requires further *in vivo* studies given the subtle differences in the phenotype induced by miR-24 on myogenic progenitors from adult and old mice, as these could be further exacerbated through changes in the satellite cell niche during aging.

We propose that changes in miR-24 and Prdx6 levels in satellite cells during aging represent an adaptive response to aging aimed at improving cellular viability and myogenic potential and decrease of cellular senescence through regulating mitochondrial ROS generation and potentially associated with it DNA damage.

#### **EXPERIMENTAL PROCEDURES**

360 Reagents.

All reagents are listed in supplementary tables.

#### Mouse samples

All experiments described herein received the ethical approval from The University of Liverpool Animal Welfare and Ethical Review Body (AWERB) and were performed in accordance with UK Home Office guidelines under the UK Animals (Scientific Procedures) Act 1986. All mice were male wild-type C57Bl/6 from Charles River (Margaret), maintained under SPF conditions and fed *ad libitum* and maintained under barrier on a 12 hours light/dark cycle. For muscle regeneration, tibialis anterior

muscle was injured by intramuscular injection of barium chloride (1.2% in saline). Tissue was collected 1, 7, 14, or 21 days after injury. Muscle was snap-frozen in liquid nitrogen and stored at -80°C. Muscle progenitor cells and satellite cells were directly isolated from fresh lower limbs muscles (extensor digitorum longus, tibialis anterior, gastrocnemius, quadriceps and soleus). For each experiment, n = 3-7 independent replicates per group were used. Young: 6-12 weeks old; adult: 6-8 months old; old: 20-24 months old. For miR-24 and Prdx6 expression in FACS-sorted satellite cells: adult: 1-8 months old; old: 20-24 months old.

#### **Human samples**

All experiments described herein involving human samples were performed according to good practice guidance and in accordance with The University of Liverpool, University Hospital Aintree Hospital and South West Wales Research Ethics Committee (Approval No: 13/WA/0374). The University of Liverpool acted as the ethics sponsor for this study. All the donors had given informed consent for enrolment in this study. Muscle biopsies were obtained from foot surgeries (extensor digitorum brevis, tibialis anterior or abductor hallucis muscles) of female patients treated for Hallux Valgus, with an average age of  $33 \pm 6.78$  years old and a Body Mass Index (BMI) < 25. For each experiment, and due to limitations in sample availability, both human primary myogenic progenitors isolated from female donors (n = 2-5 per experiment) and commercialised human primary skeletal muscle progenitors (ThermoFisher Scientific, n = 1-2 per experiment) were used. For all the experiments n = 3-7 independent replicates per group, unless stated otherwise.

#### Satellite cell isolation

Satellite cells were isolated using FACS as previously described (Yi & Rossi 2011; Soriano-Arroquia *et al.* 2016). Briefly, skeletal muscle was isolated from the hind limbs of C57Bl/6 wild type male mice and enzymatically digested with 1.5 U mL-1 collagenase D, 2.4 U mL-1 dispase II and 2.5 mM CaCl<sub>2</sub>. Cells were then dissolved in sterile FACS buffer (2% horse serum in DPBS), filtered through a 40µm cell strainer and stained with conjugated antibodies in the dark for 30 minutes on ice. Doublets were discriminated and haematopoietic and endothelial cells (PE-CD31+/CD45+) were excluded from the sorting gates. Satellite cell population was isolated as BV421-CD34+, Alexa647-Alpha7Integrin+, FICT-Sca1-, PE-CD31-, PE-CD45- and eFluor780-Viability- dye. Sorting was performed at 4°C and samples were collected in growth media (high-glucose DMEM supplemented with 10% FBS, 1% L-glutamine and 1% penicillin/streptomycin). Sorted cells were immediately centrifuged and resuspended in Qiazol (Qiagen) for total RNA isolation.

#### **RNA** isolation

For RNA isolation, cells were collected 48 hr after transfection. Total RNA from sorted cells was isolated using miRNeasy Mini Kit (Qiagen). Total RNA from primary cells was isolated using TRIzol/Chloroform standard protocol. After isolation, if necessary samples were purified using ethanol and sodium acetate. RNA concentration and quality were assessed using Nanodrop 2000.

#### Real-Time qPCR

cDNA synthesis and Real-Time qPCR were performed as previously described (Soriano-Arroquia et~al. 2016). Briefly, cDNA synthesis was performed from 500ng of RNA (for mRNA) or 100ng of RNA (for microRNA) using SuperScript II (ThermoFisher) or miRscript RT kit II (Qiagen), respectively. SYBR Green Mastermix (Qiagen) or SsoAdvanced Universal SYBR Green Supermix (BioRad) or FastSybrGreen (Thermo Fisher; 4385610) were used for Real-Time quantitative PCR. Relative expression to  $\beta$ -actin, 18S, S29,  $\beta$  -2 microglobulin (mRNA) or Snord-61 (microRNA) was calculated using delta  $C_t$  method (Soriano-Arroquia et~al. 2016).

#### Isolation of primary muscle progenitor cells from mouse and human skeletal muscles

The isolation of human and mouse primary muscle progenitor cells was performed as previously described (Soriano-Arroquia *et al.* 2017). Briefly, skeletal muscle tissue was enzymatically digested with 1.5 U mL<sup>-1</sup> collagenase D, 2.4 U mL<sup>-1</sup> dispase II and 2.5 mM CaCl<sub>2</sub>. Digested muscles were harvested on culture dishes coated with 10μg mL<sup>-1</sup> laminin and cultured with F-12 media complemented with 20% FBS, 10% horse serum, 1% L-glutamine, 1% penicillin/streptomycin and 2.5 mg/mL bFGF (Recombinant Human FGF-basic). Human cells were grown in high-glucose DMEM supplemented with 20% FBS, 10% horse serum, 1% L-glutamine and 1% penicillin/streptomycin, and mouse cells were grown in high-glucose DMEM supplemented with 10% FBS, 1% L-glutamine and 1% penicillin/streptomycin. For differentiation, both human and mouse primary muscle progenitor cells were cultured in high-glucose DMEM supplemented with 2% horse serum, 1% L-glutamine and 1% penicillin/streptomycin.

#### Transfections and immunostaining

All cells in main figures were isolated from 6 month (adult) or 24 month (old) old mice. Cells used in experiments presented in supplementary data were isolated from mice aged 1-8 months (young and adult) or 20-24 months (old). Transfections of primary cells were performed as previously described (Soriano-Arroquia *et al.* 2017). Briefly, primary cells were transfected with 100nM of miR-24-3p mimic, 100nM of miR-24-3p inhibitor, 100nM of scrambled control or 100nM of siRNA against Prdx6 using Lipofectamine 2000 transfection reagent (ThermoFisher). Cells were used at P4-P7. Cells were plated at either 80% confluency (differentiation, qPCR, western blotting), or 50% confluency (viability, proliferation, senescence, MitoTracker and MitoSox staining). Culture media was changed to

differentiation media (high-glucose DMEM complemented with 2% HS, 1% P/S, 1%  $\alpha$ -glutamine) 6 hours after transfection. No media was changed until collection or staining of the cells. Control cells were transfected with scrambled control. Immunostaining was performed 48 hr (Ki67 staining), 4 days (viability assay), 7 days (SA- $\beta$ -galactosidase staining) and 7-10 days (MF 20 staining) after transfection. RNA and protein were isolated 48 hr after transfection. Staining for MF 20 , SA- $\beta$ -galactosidase, MF 20, Ki67 and viability assay was performed as previously published methods (Soriano-Arroquia *et al.* 2017). Fluorescent SA- $\beta$ -galactosidase, Mitotracker Red, Mitosox and DNA damages were performed using Cell Event Cell senescence kit, MitoSox Red, MitotTracker Red CM-H2Xros and HCS DNA damage kits (Thermo Fisher) according to manufacturer's protocols.

For Western blotting cells were lysed in RIPA buffer and protein concentrations were calculated using Bradford reagent with BSA as standards. For immunoblotting 20µg (mouse) or 15µg (human) of protein was loaded on a 10-14% polyacrylamide gels. Following gel electrophoresis samples were transferred onto nitrocellulose membrane and total protein was stained using Ponceau S. Following washing of the membrane with TBS-T, membranes were blocked for 1h at room temperature using either 5% BSA or milk, membranes were washed 3 x 10 min in TBS-T and incubated overnight at 4C with primary antibodies (see Suppl Tables). Membranes were washed and incubated with secondary antibodies goat anti-rabbit and goat anti-mouse (Li-Cor Biosciences) and images were obtained using Odyssey Fc imaging system (Li-Cor). Quantification of blots and normalisation was performed using Image Studio Lite (Li-Cor).

#### miR:target binding reporter assay

5'UTR of Prdx6-202 transcript regions with either the wild-type or mutated miR-24-3p target sites were synthesized using GeneArt service (Thermo Scientific). The wild type or mutated sequences were subcloned into a GFP TOPO vector (Thermo Scientific). C2C12 myoblasts were cultured in 96-well plates and transfected using Lipofectamine 2000™ (Thermo Scientific) with either 200ng of the wild type or mutant sensor and with either 100nM of the miR scrambled control or 100nM miR-24 mimic. Each experiment was carried out using at least two independent plasmid preparations in triplicate. GFP fluorescence was measured 48 hr following transfections using FLUOstar Optima microplate reader (BMG Labtech).

#### Image analysis

Cells were semi-automatically quantified using Fiji and ImageJ (Schindelin et al., 2012) followed by manual correction. At least 3-6 random images from different fields of view per biological sample at 10x magnification (100x total magnification) were captured. The only exception of this rule was for human  $\beta$ -galactosidase analysis, in which a complete tiled field of view image was analysed per

biological sample. For myogenic differentiation analyses, fusion index is shown as the percentage of nuclei contained within myotubes to the total number of nuclei in each field of view. For the quantification of senescent cells, cells were counted manually (only cells showing intense blue staining were classified as senescent) or β-galactosidase activity values (BGAVs) were calculated as previously described by Shlush et al. (Shlush *et al.* 2011). Cells with a BGAV  $\geq$  15 were considered as highly senescent (SA-βgal<sup>high</sup>, characterised by an intense blue staining); cells with a BGAV between 5-14 both inclusive were considered as low senescent (SA-βgal<sup>low</sup>, characterised by an light blue staining); and cells with a BGAV < 5 were considered as non-senescent (SA-βgal<sup>non</sup>, no blue staining). All the immunostaining quantifications were manually curated. Images were captured using Nikon Eclipse Ti-E inverted confocal microscope (supplementary data) and Carl Zeiss Axiovert 200 inverted microscope (for SA-βgal staining) or EVOS M5000 and EVOS M7000 (Thermo Fisher, main figures).

#### Statistical analysis

Details of the statistical analyses used per experiment are described in the corresponding figure legend. T-test or Mann-Whitney (qPCR data which is not normally distributed) test were performed for the analysis of statistical differences between two groups as stated. One way or two-way A.N.O.V.A. followed by Tukey's multiple comparison test, or Kruskal-Wallis followed by Dunn's multiple comparison test with 95% Confidence Interval was performed to compare more than two groups as indicated where data was not normally distributed. p-value < 0.05 was considered statistically significant. All analysis was performed on raw (not normalised) data. For the transfection experiments, individual values representing the same independent biological replicate have been matched with a dotted line. Statistical analysis were performed using GraphPad Prism version 8.4.2/9.0.0 for Windows (GraphPad Software, La Jolla California USA, www.graphpad.com).

#### Gene ontology

A list of human and mouse miR-24 predicted targets were obtained from TargetScanHuman 6.2 (Lewis et al. 2005; Grimson et al. 2007; Agarwal et al. 2015). Human and mouse miR-24:targets network interaction and GO analyses were performed using Cytoscape v.3.8.0 (Shannon et al. 2003) and ClueGO v.2.5.6 plugin for Cytoscape (Bindea et al. 2009), respectively. Details of the statistics used for ClueGO are specified in the corresponding figure legend. Generally: Enrichment/Depletion (Two-sided hypergeometric test); Minimum p-value cut-off = 0.01; Correction Method = Bonferroni step down; Min GO Level = 5; Max GO Level = 8; Kappa Score Threshold = 0.4-0.55.

#### **ACKNOWLEDGEMENTS**

This work is supported by the Biotechnology and Biological Sciences Research Council (BBSRC; BB/L021668/1), the MRC and Arthritis Research UK as part of the MRC – Arthritis Research UK Centre

- 500 for Integrated Research into Musculoskeletal Aging (CIMA), Irish Research Council Award
- 501 IRCLA/2017/101, Science Foundation Ireland (19/FFP/6709) and the Wellcome Trust Institutional
- 502 Strategic Support Fund (097826/Z/11/A). QX and BMcD are funded by the Chinese Scholarship Council.
- 503 The authors would like to thank Caroline Rainer (Technology Directorate, MARIAC, University of
- 504 Liverpool), for her help with the isolation of satellite cells; Dr. Aldorada Pisconti (University of
- Liverpool) for the anti- $\alpha$ 7-integrin gift and Mr. Andy Molloy and members of the Aintree University
- Hospital (Liverpool) for providing human samples. Graphical abstract has been produced using Affinity
- 507 Designer version 1.8.5 (https://affinity.serif.com/en-gb/designer/).

#### 508 **CONFLICT OF INTERESTS**

The authors declare no conflict of interests associated with this manuscript.

#### 510 **AUTHOR CONTRIBUTIONS**

- 511 AS, JG, QX, KW, BMcD performed the experiments; AS, JG, DB, QX, BMcD and KW performed data
- analyses; all authors contributed to experimental design, statistical analyses and manuscript
- 513 preparation.

#### 514 Data availability statement

- Source data for microscopy images and FACS data have been deposited into Mendeley data set:
- 516 doi:10.17632/g7593chtxy.1

#### 517 **REFERENCES**

522523

- Agarwal V, Bell GW, Nam J-W, Bartel DP (2015). Predicting effective microRNA target sites in mammalian mRNAs. *eLife*. **4**, e05005.
- Arevalo JA, Vázquez-Medina JP (2018). The Role of Peroxiredoxin 6 in Cell Signaling. *Antioxidants* (*Basel, Switzerland*). **7**, 172.
  - Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman W-H, Pagès F, Trajanoski Z, Galon J (2009). ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics*. **25**, 1091-1093.
- Blau HM, Cosgrove BD, Ho AT (2015). The central role of muscle stem cells in regenerative failure with aging. *Nat Med*. **21**, 854-862.
- 527 Cheung TH, Quach NL, Charville GW, Liu L, Park L, Edalati A, Yoo B, Hoang P, Rando TA (2012).
  528 Maintenance of muscle stem cell quiescence by microRNA-489. *Nature*. **482**, 524-528.
- Da Silva-Azevedo L, Jähne S, Hoffmann C, Stalder D, Heller M, Pries AR, Zakrzewicz A, Baum O (2009).
  Up-regulation of the peroxiredoxin-6 related metabolism of reactive oxygen species in skeletal
  muscle of mice lacking neuronal nitric oxide synthase. *The Journal of Physiology*. **587**, 655668.
- Fry CS, Lee JD, Mula J, Kirby TJ, Jackson JR, Liu F, Yang L, Mendias CL, Dupont-Versteegden EE, McCarthy JJ, Peterson CA (2015). Inducible depletion of satellite cells in adult, sedentary mice impairs muscle regenerative capacity without affecting sarcopenia. *Nat Med.* **21**, 76-80.
- Gamez AS, Quax WJ, Demaria M (2019). Regulation of Survival Networks in Senescent Cells: From Mechanisms to Interventions.
- Gibson MC, Schultz E (1983). Age-related differences in absolute numbers of skeletal muscle satellite cells. *Muscle Nerve*. **6**, 574-580.

Aging Cell Page 28 of 50

Goljanek-Whysall K, Iwanejko LA, Vasilaki A, Pekovic-Vaughan V, McDonagh B (2016). Ageing in relation to skeletal muscle dysfunction: redox homoeostasis to regulation of gene expression. *Mamm Genome*. **27**, 341-357.

- Goljanek-Whysall K, Soriano-Arroquia A, McCormick R, Chinda C, McDonagh B (2020). miR-181a regulates p62/SQSTM1, parkin, and protein DJ-1 promoting mitochondrial dynamics in skeletal muscle aging. *Aging Cell.* **19**, e13140.
- Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP (2007). MicroRNA targeting specificity in mammals: determinants beyond seed pairing. *Mol Cell.* **27**, 91-105.
- Grounds MD (2014). The need to more precisely define aspects of skeletal muscle regeneration. *Int J Biochem Cell Biol.* **56**, 56-65.
- Horn A, Van der Meulen JH, Defour A, Hogarth M, Sreetama SC, Reed A, Scheffer L, Chandel NS, Jaiswal JK (2017). Mitochondrial redox signaling enables repair of injured skeletal muscle cells. *Sci Signal*. **10**.
- Kidane D, Chae WJ, Czochor J, Eckert KA, Glazer PM, Bothwell ALM, Sweasy JB (2014). Interplay between DNA repair and inflammation, and the link to cancer. *Crit Rev Biochem Mol Biol.* **49**, 116-139.
- Kob R, Fellner C, Bertsch T, Wittmann A, Mishura D, Sieber CC, Fischer BE, Stroszczynski C, Bollheimer CL (2015). Gender-specific differences in the development of sarcopenia in the rodent model of the ageing high-fat rat. *Journal of cachexia, sarcopenia and muscle*. **6**, 181-191.
- Lal A, Pan Y, Navarro F, Dykxhoorn DM, Moreau L, Meire E, Bentwich Z, Lieberman J, Chowdhury D (2009). miR-24-mediated downregulation of H2AX suppresses DNA repair in terminally differentiated blood cells. *Nature structural & molecular biology*. **16**, 492-498.
- Laumonier T, Menetrey J (2016). Muscle injuries and strategies for improving their repair. *Journal of Experimental Orthopaedics*. **3**, 15.
- Le Moal E, Pialoux V, Juban G, Groussard C, Zouhal H, Chazaud B, Mounier R (2017). Redox Control of Skeletal Muscle Regeneration. *Antioxidants & redox signaling*. **27**, 276-310.
- Lee RC, Feinbaum RL, Ambros V (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. *Cell.* **75**.
- Lepper C, Partridge TA, Fan C-M (2011). An absolute requirement for Pax7-positive satellite cells in acute injury-induced skeletal muscle regeneration. *Development (Cambridge, England)*. **138**, 3639-3646.
- Lewis BP, Burge CB, Bartel DP (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell.* **120**, 15-20.
- Li Q, Wang N, Wei H, Li C, Wu J, Yang G (2016). miR-24-3p Regulates Progression of Gastric Mucosal Lesions and Suppresses Proliferation and Invasiveness of N87 Via Peroxiredoxin 6. *Digestive Diseases and Sciences*. **61**, 3486-3497.
- López Grueso MJ, Tarradas Valero RM, Carmona-Hidalgo B, Lagal Ruiz DJ, Peinado J, McDonagh B, Requejo Aguilar R, Bárcena Ruiz JA, Padilla Peña CA (2019). Peroxiredoxin 6 Down-Regulation Induces Metabolic Remodeling and Cell Cycle Arrest in HepG2 Cells. *Antioxidants (Basel)*. **8**.
- Lu B, Christensen IT, Ma LW, Wang XL, Jiang LF, Wang CX, Feng L, Zhang JS, Yan QC (2018). miR-24-p53 pathway evoked by oxidative stress promotes lens epithelial cell apoptosis in age-related cataracts. *Mol Med Rep.* **17**, 5021-5028.
- Maher AC, Fu MH, Isfort RJ, Varbanov AR, Qu XA, Tarnopolsky MA (2009). Sex differences in global mRNA content of human skeletal muscle. *PloS one*. **4**, e6335-e6335.
- Mishra PJ, Song B, Mishra PJ, Wang Y, Humeniuk R, Banerjee D, Merlino G, Ju J, Bertino JR (2009). MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. *PloS one*. **4**, e8445-e8445.
- Pacifici F, Arriga R, Sorice GP, Capuani B, Scioli MG, Pastore D, Donadel G, Bellia A, Caratelli S, Coppola A, Ferrelli F, Federici M, Sconocchia G, Tesauro M, Sbraccia P, Della-Morte D, Giaccari A, Orlandi A, Lauro D (2014). Peroxiredoxin 6, a novel player in the pathogenesis of diabetes. Diabetes. 63, 3210-3220.

Page 29 of 50 Aging Cell

Pacifici F, Della-Morte D, Piermarini F, Arriga R, Scioli MG, Capuani B, Pastore D, Coppola A, Rea S, Donadel G, Andreadi A, Abete P, Sconocchia G, Bellia A, Orlandi A, Lauro D (2020). Prdx6 Plays a Main Role in the Crosstalk Between Aging and Metabolic Sarcopenia. *Antioxidants (Basel, Switzerland)*. **9**, 329.

- Redshaw Z, Sweetman D, Loughna PT (2014). The effects of age upon the expression of three miRNAs in muscle stem cells isolated from two different porcine skeletal muscles. *Differentiation; research in biological diversity*. **88**, 117-123.
- Sakellariou GK, Lightfoot AP, Earl KE, Stofanko M, McDonagh B (2017). Redox homeostasis and agerelated deficits in neuromuscular integrity and function. *J Cachexia Sarcopenia Muscle*. **8**, 881-906.
- Sambasivan R, Tajbakhsh S (2015). Adult skeletal muscle stem cells. *Results Probl Cell Differ*. **56**, 191-602 213.
  - Sannicandro AJ, Soriano-Arroquia A, Goljanek-Whysall K (2019). micro(RNA)-managing muscle wasting. *J Appl Physiol* (1985).
    - Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A (2012). Fiji: an open-source platform for biological-image analysis. *Nature Methods.* **9**, 676.
    - Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* **13**, 2498-2504.
    - Shlush LI, Itzkovitz S, Cohen A, Rutenberg A, Berkovitz R, Yehezkel S, Shahar H, Selig S, Skorecki K (2011). Quantitative digital in situ senescence-associated beta-galactosidase assay. *BMC Cell Biol.* **12**, 16.
    - Soriano-Arroquia A, Clegg PD, Molloy AP, Goljanek-Whysall K (2017). Preparation and Culture of Myogenic Precursor Cells/Primary Myoblasts from Skeletal Muscle of Adult and Aged Humans. *J Vis Exp*.
    - Soriano-Arroquia A, McCormick R, Molloy AP, McArdle A, Goljanek-Whysall K (2016). Age-related changes in miR-143-3p:lgfbp5 interactions affect muscle regeneration. *Aging Cell.* **15**, 361-369.
    - Sun Q, Zhang Y, Yang G, Chen X, Zhang Y, Cao G, Wang J, Sun Y, Zhang P, Fan M, Shao N, Yang X (2008). Transforming growth factor-beta-regulated miR-24 promotes skeletal muscle differentiation. *Nucleic Acids Res.* **36**, 2690-2699.
    - Sun Y, Wang H, Li Y, Liu S, Chen J, Ying H (2018). miR-24 and miR-122 Negatively Regulate the Transforming Growth Factor-β/Smad Signaling Pathway in Skeletal Muscle Fibrosis. *Molecular therapy. Nucleic acids.* **11**, 528-537.
- Vasudevan S (2012). Posttranscriptional upregulation by microRNAs. *Wiley Interdiscip Rev RNA*. **3**, 311-330.
  - Vicencio JM, Galluzzi L, Tajeddine N, Ortiz C, Criollo A, Tasdemir E, Morselli E, Ben Younes A, Maiuri MC, Lavandero S, Kroemer G (2008). Senescence, apoptosis or autophagy? When a damaged cell must decide its path--a mini-review. *Gerontology*. **54**, 92-99.
  - Wada S, Kato Y, Okutsu M, Miyaki S, Suzuki K, Yan Z, Schiaffino S, Asahara H, Ushida T, Akimoto T (2011). Translational Suppression of Atrophic Regulators by MicroRNA-23a Integrates Resistance to Skeletal Muscle Atrophy. *Journal of Biological Chemistry*. **286**, 38456-38465.
  - Wu X, Ji P, Zhang L, Bu G, Gu H, Wang X, Xiong Y, Zuo B (2015). The Expression of Porcine Prdx6 Gene Is Up-Regulated by C/EBPβ and CREB. *PLOS ONE*. **10**, e0144851.
- 636 Yi L, Rossi F (2011). Purification of progenitors from skeletal muscle. J Vis Exp.
- Zhu P, Zhang C, Gao Y, Wu F, Zhou Y, Wu W-S (2019). The transcription factor Slug represses p16(Ink4a) and regulates murine muscle stem cell aging. *Nature communications*. **10**, 2568-2568.

#### FIGURE LEGENDS

641

642

643

644

645

646

647 648

649

650

651

652

653

654

655

656 657

658

659

660

661

662

663

664

665

666

667668

669

670

671

672

673

674

Figure 1. miR-24 expression is affected by muscle injury and aging. (A) miR-24 is predicted to target genes and processes associated with redox balance in humans. Gene ontology (GO) analysis was performed by ClueGO plugin for Cytoscape (v.2.5.6). Statistical test used for ClueGO: Enrichment/Depletion (Two-sided hypergeometric test). p-value cut-off = 1.0E-4. Correction Method = Bonferroni step down. Min GO Level = 5; Max GO Level = 8; Number of Genes = 16; Min Percentage = 4.0; Kappa Score Threshold = 0.4. Only targets involved in 'cellular response to oxidative stress' are shown. (B) The percentage of mouse satellite cells decreases during aging (n = 4-7,  $R^2$  = 0.9484). (C-E) Myogenic progenitors from old mice are less viable, have decreased myogenic potential and display increased senescence (n = 3-6, two-tailed unpaired Student's t-test). (F) The accumulation of ROS assessed using the CM-H<sub>2</sub>DCFDA assay; mean fluorescence intensity shown. (G) Increased production of mitochondrial ROS detected by MitoSox Red in mouse myogenic progenitors during aging (n = 3, upaired t-test). (H) qPCR showing decreased expression of miR-24 in mouse satellite cells during aging. Expression relative to Snord61 is shown (n = 5-7, Mann-Whitney test). (I) Diagram representing tissue collection points following TA injury using BaCl<sub>2</sub>. (J) qPCR of miR-24 in the TA after injury. Expression relative to Snord61 is shown (n = 3, two-way A.N.O.V.A followed by Tukey's multiple comparison test with 95% Confidence Interval). Young: 6-12 weeks old; adult: 6-8 months old; old: 20-24 months old. (K) Representative images of H&E and WGA staining indicating the extent of muscle damage following BaCl2 injury of the gastrocnemius muscle from adult and old muscle. Scale bars: 200 μm. For miR-24 qPCR in satellite cells: adult: 1-8 months old; old: 20-24 months old. p-value < 0.05 was considered as statistically significant (\*). Error bars show S.E.M.

Figure 2. miR-24 regulates viability and differentiation of myogenic progenitors during aging. (A, D) Myogenic progenitors isolated from adult and old mice were transfected with miR-24 or AM24. Cells transfected with scrambled control were used as control. Scale bars: 300μm. (A) Viability assay shows viable (green), apoptotic (yellow) and necrotic (red) cells. (B) miR-24 overexpression and downregulation of its target Prdx6 resulted in significant decrease in % viable cells from old mice. (C) MF 20 (anti-myosin heavy chain; green) and DAPI (blue) immunostaining were performed for myogenic differentiation and nuclei identification, respectively. (D) Overexpression of miR-24 significantly affected the differentiation of myogenic progenitors from adult mice, inhibition of miR-24 target Prdx6 inhibited myogenic differentiation of muscle progenitors from muscle of adult and old mice, whereas miR-24 inhibition led to improved myogenesis of muscle progenitors from muscle of adult and old mice. All panels: n = 3-4, One-Way A.N.O.V.A followed by Tukeys multiple comparison test. Adult: 6 months old; old: 24 months old. p-value < 0.05 was considered as statistically significant (\*p < .05). Error bars show S.E.M.

676

677

678

679

680

681 682

683 684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

Figure 3. miR-24 overexpression and downregulation of its target gene Prdx6 lead to increased number of senescent cells through increased mitochondrial ROS generation and DNA damage. (A) Myogenic progenitors isolated were transfected with miR-24 mimic (miR-24) or anti-miR (AM24). Cells transfected with scrambled control were used as control. SA-Bgal staining (B) or fluorescent SA-Bgal staining (C) was performed for the assessment of senescent cells (blue). Scale bars: 300µm. (B, C) miR-24 overexpression and inhibition of Prdx3 resulted in a higher % of senescent cells in the adult or both mice, respectively; n = 3, One-Way A.N.O.V.A followed by Tukeys). (D) miR-24 and Prdx6 overexpression/inhibition was associated with increased p53 and p16 expression in myogenic progenitors from old mice; expression relative to 29S is shown; One-Way A.N.O.V.A followed by Tukeys. (E) MitoTracker staining of myogenic progenitors from adult and old mice indicates dysregulation of mitochondrial networks following miR-24 overexpression and Prdx6 downregulation. (F) Mitosox Red staining indicates increase in mitochondrial ROS production following miR-24 overexpression and Prdx6 downregulation. (G) Overexpression of miR-24 and inhibition of Prdx6 led to an increase in the presence of nuclei stained for phosphorylated H2Ax, a marker of DNA damage. Scale bars: 75μm (H) Quantification of Mitosox Red staining and phosphor-H2Ax staining indicate increase in ROS generation following miR-24 overexpression and Prdx6 downregulation in myogenic progenitors from adult and old mice and increase in DNA damage marker in muscle of old mice following miR-24 overexpression. miR-24 and siPrdx6 expression manipulation did not result in changes in H2ax expression (qPCR). Adult: 6 months old; old: 24 months old. p-value < 0.05 was considered as statistically significant (\*p < .05;). Error bars show S.E.M.

**Figure 4.** miR-24 fine-tunes the levels of Prdx6 levels through its target site. **(A)** qPCR showing Prdx6 expression in mouse satellite cells during aging. Expression relative to beta-actin is shown. Adult: 1-8 months old. Old: 20-24 months old (n = 5, Mann-Whitney test). **(B)** Putative miR-24-3p seed sequence in the 5' UTR of Prdx6 gene (highlighted in grey). Mutated seed sequence used for 5'UTR microRNA:mRNA target interaction is shown. Mutation is shown in red. **(C)** miR-24 directly regulates the expression of Prdx6. GFP-Prdx6 5'UTR sensor construct containing the wild type or mutated seed sequence were transfected into C2C12 myoblast cell line and co-transfected with miR-24 or scrambled control (Scr). The wild type construct transfected with miR-24 mimic shows less GFP fluorescence intensity compared to the scrambled control, but not in the mutated construct. (Representative data shown; n = 3, two-tailed unpaired Student's t-test). **(D, E)** qPCR showing the expression of Prdx6 after microRNA mimic or antagomiR (AM24) transfection in primary myogenic progenitors isolated from adult **(D)** and old mice **(E)**. Expression relative to 18S is shown. Adult: 6-8 months old; old: 20-24 months old (n = 3-7, Kruskal-Wallis test followed by Dunn's multiple comparisons test with 95% Confidence Interval). **(F, G)** Western blotting indicating changes in PRDX6 levels following miR-24

Aging Cell


overexpression or inhibition suggesting miR-24 fine-tuning the levels of PRDX6 rather than being a master regulator of PRDX6 levels. miR-24 overexpression and inhibition or downregulation of PRDX6 had no effect on the levels of antioxidant protein PRDX3, n=3. One-Way A.N.O.V.A followed by Tukey's multiple comparison. For all the figures unless stated otherwise: adult: 6 months old; old: 24 months old. p-value < 0.05 was considered as statistically significant (\*p < .05). Error bars show S.E.M.

Figure 5. miR-24 and Prdx6 regulate viability and differentiation of human primary myoblasts. (A, B) Human primary myogenic progenitor cells isolated from adults were transfected with miR-24 or AM24 or siRNA for Prdx6. Cells transfected with scrambled RNA were used as control (Control). MF 20 (antimyosin heavy chain; green) and DAPI (blue) immunostaining were performed for myogenic differentiation and nuclei identification, respectively. Viability assay was performed with ethidium bromide and acridine orange for the assessment of viable (green), apoptotic (yellow) and necrotic (red) cells. SA-βgal staining was performed for the assessment of senescent cells (blue). Scale bars: 200μm. (C, D) miR-24 overexpression and downregulation of Prdx6 resulted in decreased number of viable cells, as well as thinner myotubes containing fewer nuclei (n = 3, One-Way A.N.O.V.A followed by Tukeys multiple comparison). p-value < 0.05 was considered as statistically significant (\*p < .05). Error bars show S.E.M. Scale bars: 300μm.

Figure 6. miR-24 and its target regulate senescence of human myogenic progenitors through mitochondrial ROS production. (A) Human myogenic progenitors isolated were transfected with miR-24 mimic (miR-24) or anti-miR (AM24). Cells transfected with scrambled control were used as control. SA-βgal staining (B) or fluorescent SA-βgal staining (C) was performed for the assessment of senescent cells (blue). Scale bars: 300μm. (B) Quantification of senescent cells indicates increase in the proportion and number of senescent cells following miR-24 overexpression and downregulation of Prdx6 expression. (C) MitoTracker Red staining indicates changes in mitochondrial morphology following miR-24 overexpression and downregulation of siPrdx6 levels. (D, F) Mitosox Red staining indicates increased mitochondrial ROS levels following miR-24 overexpression and downregulation of Prdx6 expression. Scale bars: 75μm. (E, F) No significant changes were detected in DNA damage marker, phosphorylated H2Ax. (G) Western blot indicating miR-24 fine-tuning the expression of Prdx6 rather than being a master regulator of its expression. No changes were detected in the levels of antioxidant protein levels: PRDX3 following changes in miR-24 or Prdx6 expression. One-way A.N.O.V.A. followed by Tukey's multiple comparison test with 95% Confidence Interval). p-value < 0.05 was considered as statistically significant (\*p < .05). Error bars show S.E.M.


160x204mm (300 x 300 DPI)

Aging Cell Page 34 of 50




381x444mm (300 x 300 DPI)

Page 35 of 50 Aging Cell




406x579mm (300 x 300 DPI)

Aging Cell Page 36 of 50




160x239mm (300 x 300 DPI)

Page 37 of 50 Aging Cell




151x91mm (300 x 300 DPI)

Aging Cell Page 38 of 50



136x112mm (300 x 300 DPI)

Page 39 of 50 Aging Cell



49x56mm (600 x 600 DPI)





Fig. S2






Figure S3.

## Human primary myoblasts




Figure S4.

Page 43 of 50 **Aging Cell** 




Figure S5.




Figure S6.

Page 45 of 50 Aging Cell

## **Supplementary figure legends:**

**Figure S1.** Illustration showing the isolation of quiescent satellite cells by FACS (fluorescence activated cell sorting). The satellite cells population was positive for CD34, highly-positive for alpha7-integrin, and negative for Sca1, CD31 and CD45.

**Figure S2. (A)** qPCR showing the expression of miR-24 after microRNA mimic or antagomiR (AM24) transfection in primary myogenic progenitors isolated from adult and old mice. Expression relative to Snord61 is shown (n = 3-7, adult: 6-8 months old; old: 20-24 months old). F-test compared to control. p-value < 0.05 was considered as statistically significant (# p < .05; ## p < .01; ### p < .001; #### p < .0001). Error bars show S.E.M. **(B)** qPCR showing Prdx6 expression in mouse tibialis anterior muscle during aging. Expression relative to 6-2 microglobulin is shown (n = 3-4, adult: 6-8 months old; old: 20-24 months old). Mann-Whitney test (\* < .05; \*\*p < .01; \*\*\*p < .001). Error bars show S.E.M.

Figure S3. miR-24 regulates function of myogenic progenitors during aging. (A) Viability assay shows viable (green), apoptotic (yellow) and necrotic (red) cells. miR-24 overexpression resulted in decreased viable cells from both adult and old mice. miR-24 inhibition also affected viability of cells isolated from old mice (n = 6-7, two-tailed unpaired Student's t-test compared to control). (B) MF 20 (anti-myosin heavy chain; green) and DAPI (blue) immunostaining were performed for myogenic differentiation and nuclei identification, respectively. miR-24 overexpression resulted in decreased myotube diameter whereas miR-24 inhibition resulted in bigger myotubes in myogenic progenitors from old mice compared to control (n = 3-4, two-tailed unpaired Student's t-test compared to control). (C) SA-βgal staining performed on replicatively senescent cells from adult and old mice was performed for the assessment of senescent cells (blue). Scale bars: 200µm. Changes in miR-24 levels affected the proportion of senescent cells, (n = 4-6, two-tailed unpaired Student's t-test compared to control). (D) Ki67 staining of primary myogenic progenitors demonstrates no difference in cell proliferation following miR-24 overexpression or inhibition. Scale bars: 200μm. n = 4-7; two-tailed unpaired Student t-Test. (E) The expression of senescence-associated genes was affected following miR-24 overexpression in myogenic progenitors from old mice. (n = 3-7, Kruskal-Wallis test followed by Dunn's multiple comparisons test with 95% Confidence Interval; expression relative to 18S is shown). All panels: Cells transfected with scrambled RNA were used as control group (Control); adult: 6-8 months old; old: 20-24 months old; p-value < 0.05 was considered as statistically significant (\*p < .05; \*\*p < .01; \*\*\*p < .001). Error bars show S.E.M.

**Figure S4.** miR-24 regulates differentiation, viability and senescence of human primary myogenic progenitors. Human primary myogenic progenitor cells isolated from adults were transfected with miR-24 or AM24. Cells transfected with the empty vector or scrambled control were used as control (Control). **(A)** MF 20 (anti-myosin heavy chain; green) and DAPI (blue) immunostaining were performed for myogenic differentiation and nuclei identification, respectively. **(B)** Viability assay was performed with ethidium bromide and acridine orange for the assessment of viable (green), apoptotic (yellow) and necrotic (red) cells. **(C)** SA-βgal staining was performed for the assessment of senescent cells (blue). Scale bars: 200μm. **(D)** Ki67 staining indicates no effects of miR-24 on human myoblast proliferation. miR-24 overexpression resulted in thinner myotubes, less viability and increased number of senescent cells (n = 3-4, two-tailed unpaired Student's t-test compared to Control group). p-value < 0.05 was considered as statistically significant (\*p < .05; \*\*p < .01; \*\*\*p < .001). Error bars show S.E.M.

**Figure S5.** Negative control for MitoSox Red staining and Mitosox Red staining in cells not treated or treated with H2O2 to test the working concentration od MitoSox Red.

Figure S6. Original western blot images.

**Supplementary table 1:** Age and gender of the patients donating a muscle biopsy for the isolation of human primary myogenic progenitor cells.

| Donor ID | Age (years) | Gender | ВМІ |
|----------|-------------|--------|-----|
| Donor 1  | 32          | Female | <25 |
| Donor 2  | 34          | Female | <25 |
| Donor 3  | 32          | Female | <25 |
| Donor 4  | 31          | Female | <25 |
| Donor 5  | 22          | Female | <25 |
| Donor 6  | 35          | Female | <25 |

Supplementary table 2: Antibodies used for the isolation of satellite cells by FACS.

| FACS Conjugated antibody   | Company                         | Catalogue<br>number | Dilution | FACS Aria<br>filter |
|--|---------------------------------|---------------------|----------|---------------------|
| Anti-CD31-PE: PE Rat Anti-Mouse CD31. Clone: MEC 13.3. Isotype: Rat IgG2a, κ. 0.2 mg/ml                | BD Biosciences<br>PharmingenTM  | 561073              | 1:1333   | 575/26 (PE)         |
| Anti-CD-45/PE: PE Rat Anti-Mouse CD45. Clone: 30-F11. Isotype: Rat IgG2b, κ. 0.2 mg/ml                 | (BD Biosciences<br>PharmingenTM | 553081              | 1:1333   | 575/26 (PE)         |
| Anti-Sca1/FICT: FICT Rat Anti-mouse Ly-<br>6A/E. Clone: E13-161.7. Isotype: Rat<br>IgG2a, κ. 0.5 mg/ml | BD Biosciences<br>PharmingenTM  | 553335              | 1:1333   | 530/30 (FITC)       |

| Anti-Alpha 7 Integrin 647. Clone: R2F2. | AbLab            | N/A      | 1:2000 | 660/20 (APC)   |
|---|------------------|----------|--------|----------------|
| Isotype: Rat IgG2b. 1.0 mg/ml           | Ablab            | 14/7     | 1.2000 | 000/20 (Al C)  |
| BV421 Rat Anti-Mouse CD34 Clone         | BD Biosciences   | 562608   | 1:1000 | 450/40         |
| RAM34 (RUO). 0.2 mg/ml                  | /ml PharmingenTM |          | 1.1000 | (Pacific Blue) |
| Fixable Viability Dye eFluor 780 (label | Affimetrix       | 65-0865- | 1:4000 | 780/60 (APC-   |
| dead cells)                             | eBiosciences     | 14       | 1.4000 | Cy7)           |

## **Supplementary table 3:** List of primers, oligos and antibodies used for the study.

| Gene                              | Company       | Organism | Sequence (5'-3')/ Cat. Number    |
|-----------------------------------|---------------|----------|----------------------------------|
| Hs_SNORD61_11 miScript Primer     | Qiagen        | Human,   | MS00033705                       |
| Assay                             |               | mouse    |                                  |
| Hs_miR-24_1 miScript Primer Assay | Qiagen        | Human,   | MS00006552. Targets mature miR:  |
|                                   |               | mouse    | UGGCUCAGUUCAGCAGGAACAG           |
| Beta-actin Forward                | Sigma-Aldrich | Mouse    | GATCAAGATCATTGCTCCTCCTG          |
| Beta-actin Reverse                | Sigma-Aldrich | Mouse    | AGGGTGTAAAACGCAGCTCA             |
| 18S rRNA Forward                  | Sigma-Aldrich | Mouse    | CGGCTACCACATCCAAGGAAGG           |
| 18S rRNA Reverse                  | Sigma-Aldrich | Mouse    | CCCGCTCCCAAGATCCAACTAC           |
| Beta-2 microglobulin Forward      | Sigma-Aldrich | Mouse    | GGAGAATGGGAAGCCGAACA             |
| Beta-2 microglobulin Reverse      | Sigma-Aldrich | Mouse    | TCTCGATCCCAGTAGACGGT             |
| p16 Forward                       | Sigma-Aldrich | Mouse    | TGGTCACTGTGAGGATTCAGC            |
| p16 Reverse                       | Sigma-Aldrich | Mouse    | GTTGCCCATCATCATCACCTGG           |
| p21 Forward                       | Sigma-Aldrich | Mouse    | ATCCAGACATTCAGAGCCACAG           |
| p21 Reverse                       | Sigma-Aldrich | Mouse    | TCGGACATCACCAGGATTGG             |
| Prdx6 Forward                     | Sigma-Aldrich | Mouse/   | TTGATGATAAGGGCAGGGAC             |
|                                   |               | Human    |                                  |
| Prdx6 Reverse                     | Sigma-Aldrich | Mouse/   | CTACCATCACGCTCTCTCCC             |
|                                   |               | Human    |                                  |
| Tumor protein p53 Forward         | Sigma-Aldrich | Mouse    | CACGTACTCTCCTCCCCTCAAT           |
| Tumor protein p53 Reverse         | Sigma-Aldrich | Mouse    | AACTGCACAGGGCACGTCTT             |
| mPRDX6-202 5'UTR Forward          | Sigma-Aldrich | Mouse    | GCCCGCCCACTCGGCCAGC              |
| mPrdx6-202 5'UTR Reverse          | Sigma-Aldrich | Mouse    | AGCAACCCTCCGGGCATGGC             |
| mPrdx6-202 5'UTR WT               | Sigma-Aldrich | Mouse    | GCCCGCCCACTCGGCCAGCACTGA         |
|                                   |               |          | TCTAGGTCTCCGCAG <u>GAGCC</u> CGC |
|                                   |               |          | CCGCTGCTCACTGCTGCGGCTGCGC        |
|                                   |               |          | CTCCTTGTTCTCAGCGTCACCAC          |
|                                   |               |          | TGCCGCCATGCCCGGAGGGTTGCT         |

| mPrdx6-202 5'UTR 24 MUT          | Sigma-Aldrich   | Mouse   | GCCCGCCCACTCGGCCAGCACTGA         |
|----------------------------------|-----------------|---------|----------------------------------|
| 1111 Taxo 202 3 0 111 2 1 1110 1 | Jigina / lianen | iviouse |                                  |
|                                  |                 |         | TCTAGGTCTCCGCAG <u>GATCC</u> CGC |
|                                  |                 |         | CCGCTGCTCACTGCTGCGGCTGCGC        |
|                                  |                 |         | CTCCTTGTTCTCAGCGTCACCAC          |
|                                  |                 |         | TGCCGCCATGCCCGGAGGGTTGCT         |
| Bcl-2 Forward                    | Sigma-Aldrich   | Mouse   | CTGCAAATGCTGGACTGAAA             |
| Bcl-2 Reverse                    | Sigma-Aldrich   | Mouse   | TCAGGAGGGTTTCCAGATTG             |
| H2ax Forward                     | Sigma-Aldrich   | Mouse   | GGCCTGTGGACAAGAGTTCTAT           |
| H2ax Reverse                     | Sigma-Aldrich   | Mouse   | GCCCATTAAATCTCCCCACT             |
| P53 Forward                      | Sigma-Aldrich   | Mouse   | CACGTACTCTCCTCCCCTCAAT           |
| P53 Reverse                      | Sigma-Aldrich   | Mouse   | AACTGCACAGGGCACGTCTT             |
| Bcl-2 Forward                    | Sigma-Aldrich   | Human   | TCGCCCTGTGGATGACTGA              |
| Bcl-2 Reverse                    | Sigma-Aldrich   | Human   | CAGAGACAGCCAGGAGAAATCA           |
| H2ax Forward                     | Sigma-Aldrich   | Human   | CATGTCGGGCCGCGCAA                |
| H2ax Reverse                     | Sigma-Aldrich   | Human   | GTGGCGCTGGTCTTCTTG               |
| P16 Forward                      | Sigma-Aldrich   | Human   | GAAGGTCCCTCAGACATCCCC            |
| P16 Reverse                      | Sigma-Aldrich   | Human   | CCCTGTAGGACCTTCGGTGAC            |
| P21 Forward                      | Sigma-Aldrich   | Human   | GGCAGACCAGCATGACAGATTTC          |
| P21 Reverse                      | Sigma-Aldrich   | Human   | CGGATTAGGGCTTCCTCTTGG            |
| S29 Forward                      | Sigma-Aldrich   | Mouse/  | ATGGTCACCAGCAGCTCTA              |
|                                  |                 | Human   |                                  |
| S29 Reverse                      | Sigma-Aldrich   | Mouse/  | GTATTTGCGGATCAGACCGCT            |
|                                  |                 | Human   |                                  |

## **Supplementary table 4:** Table of reagents used for the experiments.

| Product                               | Company                 | Catalogue number       |
|---------------------------------------|-------------------------|------------------------|
| Barium chloride                       | Sigma-Aldrich           | 202738                 |
| AllStars Negative Control siRNA Print | Qiagen                  | 1027280                |
|                                       |                         | (discontinued)         |
| miRIDIAN Scr control                  | Dharmacon               | IN-122262-00-70        |
| Syn-mmu-miR-24-3p                     | Qiagen                  | MSY0000219             |
| Anti-mmu-miR-24-3p                    | Qiagen                  | MIN0000219             |
|                                       |                         | (discontinued)         |
| Anti-miR-24-3p                        | Dharmacon               | IH-122261-00-70        |
| Mouse Prdx6 siRNA                     | ThermoFisher Scientific | s62375 (discontinued), |
|                                       |                         | s62376                 |

| Human Prdx6 siRNA                              | ThermoFisher Scientific   | s18428      |
|--|---------------------------|-------------|
|  |                           | s18429      |
| Lipofectamine 2000                             | ThermoFisher Scientific   | 11668019    |
| MF20 primary antibody. Antigen: myosin,        | Developmental Studies     | MF20-c 2ea  |
| sarcomere (MHC). 211 ug/ml                     | Hybridoma Bank            |             |
| Rabbit mAb to Ki67 [SP6].                      | Abcam                     | ab16667     |
| Goat anti-Mouse IgG (H+L) Secondary Antibody,  | Invitrogen                | A-11029     |
| Alexa Fluor 488 conjugate.                     |                           |             |
| Goat anti-Rabbit IgG (H+L) Secondary Antibody, | ThermoFisher Scientific   | A-11034     |
| Alexa Fluor 488 conjugate.                     |                           |             |
| DAPI (4',6-Diamidino-2-Phenylindole,           | Sigma-Aldrich             | D9542       |
| Dihydrochloride)                               |                           |             |
| Senescence β-Galactosidase Staining Kit        | Cell Signaling Technology | 9860        |
|  |                           |             |
| Cell Event Cell senescence kit                 | Thermo Fisher             | C10850      |
| Acridine Orange hydrochloride solution, 10     | Sigma-Aldrich             | A8097       |
| mg/mL in H₂O                                   |                           |             |
| Ethidium bromide solution. BioReagent, for     | Sigma-Aldrich             | E1510       |
| molecular biology, 10 mg/mL in H₂O             |                           |             |
| Methanol                                       | Fisher                    | M/4000/PC17 |
| PBS (immunostaining)                           | Sigma-Aldrich             | P4417       |
| Tween-20                                       | Sigma-Aldrich             | P1379       |
| Wheat Germ Agglutinin (WGA), Fluorescein       | Vector Laboratories       | FL-1021     |
| Fluoromount                                    | ThermoFisher              | 00-4958-02  |
| DAPI (4',6-Diamidino-2-Phenylindole,           | Sigma-Aldrich             | D9542       |
| Dihydrochloride). 1mg/ml                       |                           |             |
| miRNeasy Mini Kit                              | Qiagen                    | 217004      |
| TRIzol Reagent                                 | Life Technologies         | 15596-018   |
| Chloroform:Isoamyl alcohol 24:1                | Sigma-Aldrich             | C0549       |
| Isopropanol                                    | Sigma-Aldrich             | I9516       |
| RNAse-free water                               | Sigma-Aldrich             | 3098        |
| Sodium acetate                                 | Sigma-Aldrich             | S2889       |
| Nanodrop 2000                                  | ThermoFisher Scientific   | N/A         |
| Superscript II Reverse Transcriptase           | Life Technologies         | 18064       |
| Random Hexamers (50 μM)                        | ThermoFisher              | N8080127    |
| 25X dNTP Mix (100 mM)                          | ThermoFisher              | 4368814     |
| RiboLock RNase Inhibitor (40 U/μL)             | ThermoFisher              | EO0381      |

| miRScript RT II                               | Qiagen                  | 218161     |
|---|-------------------------|------------|
| miRScript SybrGreen PCR Kit                   | Qiagen                  | 218073     |
| T100 Thermal Cycler                           | Bio-Rad                 | 1861096    |
| CFX Connect Real-Time PCR Detection System    | Bio-Rad                 | 1855201    |
| RNU-6 qPCR primer                             | Qiagen                  | MS00033740 |
| Snord-61 qPCR primer                          | Qiagen                  | MS00033705 |
| miR-24_1 miScript Primer Assay                | Qiagen                  | MS00006552 |
| Select agar                                   | Sigma-Aldrich           | A5054      |
| MyTaq Red Mix                                 | Bioline                 | BIO-25043  |
| GeneJET Genomic DNA Purification Kit          | Thermo Scientific       | K0721      |
| One Shot TOP10 Chemically Competent E. coli   | Invitrogen              | C404010    |
| SYBR Safe DNA Gel Stain                       | Invitrogen              | S33102     |
| DNA Gel Loading Dye (6X)                      | Thermo Scientific       | R0611      |
| UltraPure Agarose                             | Invitrogen              | 16500500   |
| GFP Tag Antibody, ABfinity Rabbit Monoclonal  | ThermoFisher Scientific | G10362     |
| CM-H2DCFDA (General Oxidative Stress          | Invitrogen              | C6827      |
| Indicator)                                    |                         |            |
| FLUOstar OPTIMA microplate reader             | BMG Labtech             | N/A        |
| Hydrogen peroxide solution 30 % (w/w) in H2O, | Sigma-Aldrich           | H1009      |
| contains stabilizer                           |                         |            |
| 1x RBC (Red Blood Cell) Lysis Buffer          | eBioscience             | 00-4333-57 |
| FACS Aria III Flow Cytometer                  | BD Biosciences          | N/A        |
| MitoSox Red                                   | Thermo Fisher           | M36008     |
| MitotTracker Red CM-H2Xros                    | Thermo Fisher           | M7513      |
| HCS DNA damage kit                            | Thermo Fisher           | H10292     |
| C1 confocal laser scanning microscope system. | Nikon                   | N/A        |
| 10x magnification.                            |                         |            |
| Axiovert 200 inverted microscope. 10x         | Carl Zeiss              | N/A        |
| magnification.                                |                         |            |
| EVOS M5000                                    | Thermo Fisher           | N/A        |
| EVOS M7000                                    | Thermo Fisher           | N/A        |
| SOD1  | Abcam                   |            |
| HSP70   | Abcam                   | Ab181606   |